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ABSTRACT
Bone loss associated with musculoskeletal trauma or metabolic diseases 
often requires bone grafts. Autograft or allograft bones are limited in supply. 
Therefore* development of synthetic bone graft materials is an active area of 
research. For several years the biomaterials group at LSUHSC-Shreveport has 
been investigating the use of chitosan purified from crawfish shells using a 
process patented by my research advisor, Dr. Debi Mukherjee.
Chitin is a polysaccharide that exists in fungi, exoskeleton of insects and 
outer shell of crustaceans. It is biocompatible, osteoconductive, antimicrobial, 
biodegradable, non-toxic, haemostatic, fungicidal, and the second most 
abundant natural polysaccharide on earth. Removal of the acetyl group from 
chitin forms chitosan. Chitosan is more useful due to the presence of amino 
groups that impart a positive charge to the molecule. This positive charge 
interacts with cells or can act as a binding site for other functional groups 
thereby expanding the role of chitosan molecules.
The objectives of this study are:
1. Test for the presence of bone in grafted and ungrafted defects 
and compare the results among the different groups.
2. Test and compare the differences in stiffnesses and fracture loads 
among the different groups.
iii
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3. Test, via microcomputed tomography, defect reduction in samples
treated with the graft.
4. Test for the amorphous nature of crawfish chitosan.
5. Compare the purity of crawfish chitosan extracted using Dr. Debi
Mukherjee’s procedure with commercially available chitosan.
The first portion of this experiment was characterization of crawfish 
chitosan, extracted using a method patented by Dr. Debi Mukherjee, to 
determine the individual chemical “fingerprint” of crawfish chitosan. Teste 
established that crawfish chitosan contains identical functional groups as 
chitosan monomer and chitosan glutamate and possessing an amorphous 
structure.
In the second portion of this study, purified chitosan was mixed with 
cultured osteoblasts and compounded with a calcium salt creating a bone graft 
paste. Eighteen male Lewis rate underwent the surgical procedure. A critical 
size defect was created in rat femurs following a published protocol and 
repaired through use of a metal plate with and without crawfish chitosan bone 
graft paste. Histological examination and bone graft analysis of defected areas 
demonstrated the presence of bone in defect areas that were filled with 
experimental paste material and reduced or no bone growth on control femurs.
Chitosan possesses the necessary properties, when combined with 
plaster of Paris and osteoblasts, to create a bone graft that is osteoconductive, 
osteoinductive and osteogenic.
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CHAPTER 1
INTRODUCTION
Bone loss associated with musculoskeletal trauma or metabolic diseases 
often require bone grafting. Ideal bone grafts possess osteoinductive, 
osteogenic, and osteoconductive characteristics. Osteoinductivity is the ability to 
cause undifferentiated mesenchymal cells to differentiate into chondrocytes and 
osteoblasts leading to bone formation [9,15,16,53,55,63,87,103], Osteogenicity 
is the ability to form new bone with only components contained in the graft, living 
cells that are capable of differentiation into bone [9,53,55,87,103]. 
Osteoconductivity is the ability to support vascular and bone ingrowth from the 
recipient bed into the graft site [9,15,53,55,87,103]. There are four types of bone 
grafts: autograft, allograft, synthetic graft and xenograft.
Bone Grafts
Autoaraft
Autografts have long been considered the gold standard and the only type 
of bone graft that is osteoconductive, osteogenic and osteoinductive [94]. 
Autografts contain all the proteins, growth hormones and structural integrity of 
innate bone and are traditionally harvested from the iliac crest, ribs, proximal tibia 
and distal femur, although harvesting from the iliac crest is preferred
1
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{86,87,94,123]. Cancellous grafts are revascularized faster than cortical grafts 
and are repaired completely [15]. Cancellous bone grafts are repaired by 
creeping substitution which initially involves appositional bone growth, cortical 
bone grafts are repaired through a reverse creeping substitution [15,55]. Cortical 
bone is primarily used in load bearing situations. Burchardt reported cortical 
grafts remain as necrotic and viable bone, whereas cancellous bone grafts are 
completely incorporated [15]. Bauer and Muschler reported optimum skeletal 
incorporation with vascularized cancellous autografts [9]. Non-vascularized 
cortical autografts demonstrated superior strength and provided an 
osteoconductive substrate for bone formation [9]. Autografts possess no risk of 
viral transmission. While autografts have many positive attributes, a few serious 
side effects can occur. Autograft harvesting causes additional pain through a 
secondary surgical site [32,94], in addition to increased costs. Pain can be 
minor, post-operatively, or chronic, lasting several months (15% of patients report 
pain lasting more than three months [103]). Level of pain is associated with 
amount of bone dissected for grafting [103]. Risk of infection is increased due to 
a second surgical site [32,94]. Since bone for the graft is harvested from the 
patient, autografts elicit no immunological response, but are in limited supply. 
Allograft
An allograft is a bone graft composed of bone harvested from a cadaveric 
donor. Allografts are osteoinductive and osteoconductive, they contain some 
proteins necessary for bone formation, but most osteoinductive components are 
destroyed during sterilization. Allografts have a higher absorption rate and lower
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
3percentage of revascularization compared to autografts [32], probably due to 
protein conformational changes which occur during sterilization. Allografts 
contain no viable cells therefore osteogenic potential is non-existent [32], The 
lack of viable cells is caused by methods used to sterilize, in an effort to prevent 
viral transmission. Even though donated bone is treated to prevent viral 
transmission, viral transmission is still a possibility [86J, The risk of contracting 
HIV from allografts has been reported as <1 per 1,000,000, only two allografts 
have been linked to transmission of the AIDS virus out of 3,000,000 recorded 
transplants [53,55,86,103,147]. These treatments, freezing and irradiation, alter 
not only incorporation of the graft, they alter structural characteristics [55,86,87], 
probably by changing protein confirmation. Differences are seen between 
osteoinductivity, osteoconductivity and method of sterilization [9,32]. Since bone 
is harvested from a donor, allogenic bone grafts elicit a larger immune response 
[9,32,53]; they cause less pain due to presence of only a primary surgical site 
and decrease risk of infection. Burchardt describes three types bone repair with 
allografts [15]. Type I bone repair is normal repair along a clinically acceptable 
course without any fatigue failures. Type II bone repair occurs when significant 
genetic differences exist between the donor and recipient, chronic repair. The 
exact mechanisms of genetic acceptance or rejection is unknown, but Bauer and 
Muschler report no clear link between the extent of graft incorporation and 
degree of human leukocyte antigen (HLA) matching [9]. HLA is a group of genes 
that encode for cell surface antigen presenting proteins that are responsible for
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
4immunological transplant related reactions. Type III bone repair is quickly and 
completely resorbed with no sign of initial defect.
Demineralized Bone Matrix
Demineralized bone matrix is processed allograft bone [8,32], cortical 
bone is the preferred source as it possesses a lower potential for immunological 
reaction and is more osteoinductive than cancellous bone [16]. Demineralized 
bone matrix is composed of allograft bone that has been treated with acid to 
remove mineral components [123] but leave behind necessary growth factors 
and other proteins that facilitate bone growth [32,54,85,89,125,147]. Since 
demineralized bone matrix is a derivative of natural bone, it is biocompatible and 
allows for complete healing of critical defects [28]. Demineralized bone matrix is 
osteoconductive [9] and due to acid extraction, has little risk of viral transmission 
[147]. Due to the presence of collagen, growth factors and proteins (bone 
morphogenic proteins), demineralized bone matrix is osteoinductive [25,32]. 
While demineralized bone matrix offers osteoconductivity and osteoinductivity, 
demineralized bone matrix offers no structural support [54,125,147], therefore 
any use of demineralized bone matrix must be augmented with other fixation. 
Bone Morphogenic Protein
Bone morphogenic proteins (BMP) are low molecular weight non- 
collagenous proteins naturally present that induce bone formation. During 
mechanostimuiation, bone stress causes a release of alkaline phosphatase, 
which raises pH of surrounding tissue [99]. Increase in pH causes recruitment of 
macrophages and fibroblasts which secrete growth factors and cytokines. A
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
5portion of released growth factors are bone morphogenic proteins. BMP2, BMP4 
and BMP7 activate Cfbal (core bonding factor alpha 1) gene which encodes 
Cfbal transcription factor. Cfbal directly regulates the amount of matrix 
deposited [5,54]. Due to BMP's important role in ossification, recombinant 
human BMPs (rhBMP) have been developed [53,58,123,143]. RhBMPs possess 
the ability to speed healing by inducing endochondral ossification [53], and since 
BMPs are naturally derived, they initiate no immunological reactions [147]. 
Nanograms of naturally occurring BMP initiate healing, where micrograms of 
rhBMP are necessary to perform identical tasks [58,143]. Research has yet to 
be completed on the long term effects of increased levels of rhBMPs on other 
tissues. Burg, Porter and Kellum reported the effectiveness of rhBMP2 and 
rhBMP7 in inducting bone formation [16].
Xenograft
A xenograft is a graft containing components from other species. These 
grafts fail due to severe immunogenic responses. However, derivatives from 
tissues of other species have shown promising results. Several groups have 
reported processed bovine collagen from skin and bone demonstrates 
biocompatibility [9,123]. Components from skin or bone from other species is 
preferred over using whole tissue, as whole bovine tissue can transmit disease 
causing prions. Prions, proteins that function as viruses, cause diseases such as 
Bovine Spongiform Encephalopathy (BSE) or Mad Cow Disease [154], 
Creutzfeldt-Jakob disease in humans.
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6Synthetic Bone Graft
A synthetic bone graft is primarily formulated from materials that do not 
contain organic components of bone. Synthetic bone grafts avoid many 
problems caused by use of natural bone in bone grafts. Viral transmission, 
additional surgical site and immunological reaction are all factors that can be 
avoided or reduced through use of a synthetic bone graft. Viral transmission is 
not a concern since natural components can be sterilized or otherwise treated to 
remove viral contaminants present. Individual components of a synthetic bone 
graft can be treated to remove any harmful contaminants prior to addition to the 
graft, without affecting other more sensitive components. The second harvesting 
site is not needed; this reduces secondary site morbidity and decreases surgical 
costs. Components used in synthetic bone grafts are tested for biocompatibility 
prior to addition to the graft; this reduces or eliminates any immunological 
reactions. Most synthetic bone grafts are soluble in acidic pH, Bauer and 
Muschler report that due to solubility of synthetic bone grafts in acidic pH, 
macrophages will digest graft particles without initiation of an inflammatory 
response [9]. In addition to osteoconductivity, osteoinductivity and osteogenicity, 
porosity and interconnectivity are important in bone grafting. Natural bone has a 
pore diameter of 200-900 microns [94,137], synthetic bone graft pore size of 100 
to several hundred microns is necessary for bone Ingrowth [10,161]. Porosity is 
important for angiogenesis and calcification. Blood vessel formation dictates the 
ossification process. Small pores limit angiogenesis, therefore limiting oxygen 
transport, leading to local hypoxic conditions which favor endochondral
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
7ossification [137], Larger pore sizes, 100pm and up, prevent hindrance of 
angiogenesis, thereby allowing oxygen transport and promoting 
intramembranous ossification [137]. Porosity also affects bone ingrowth. As the 
degree of porosity increases, the speed and amount of ingrowth increases 
[58,123,154]. Beppu and Santana report increased porosity, as well as higher 
contact area which offer improved anchorage conditions for mineralization 
deposits [10]. Hing et al. reported porosity as a major contributor to 
osseointegration. Increased levels of microporosity promoted ingrowth of dense 
new bone earlier than bone grafts with less microporosity [59]. Microporosity 
was found to alter the dynamics and pattern of osseointegration [59].
Hvdroxvaoatite. Hydroxyapatite, Ca™ (PO ^O Hfe with a Ca:P ratio of 5:3 
(1.66), is hydrated calcium phosphate cement most often mistaken for the 
inorganic phase of bone [58]. Hydroxyapatite has a similar, but not identical, 
crystallographic structure to natural bone mineral [58]. Due to structural 
similarities, hydroxyapatite has been used as a synthetic bone graft 
[13,26,28,32,58,68,76]. Hydroxyapatite is biocompatible [32], osteoconductive 
[32], non-toxic [32], elicits no immune response [32], and provides structural 
support under compression [53], Hydroxyapatite is not osteoinductive [32], it 
contains no proteins, and possesses negligible pores [32], which indirectly 
inhibits angiogenesis. When used as a bone graft, hydroxyapatite particles 
migrated and settled [32,68,76], which led to a lack in significant resorption 
[26,32], Gazdag et al. reported that due to lack of resorption and particle 
migration, large segments will remain at the repair site for up to ten years [53].
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8Calcium Phosphate Cement. Calcium phosphate cement is a bone 
substitute material that crystallizes resulting in resorbable microporous 
hydroxyapatite [28,103]. Calcium phosphate cement bonds to bone [28], 
provides structural support under compression [28,103], is biodegradable [28], 
and will restore bone contour [28]. Several different varieties of calcium 
phosphate salts are available ranging from tricalcium phosphate (TCP) to 
bioglass. Each is biodegradable, osteoconductive and chemically able to bond to 
bone. They are either non-porous (bioglass) [103] or microporous (TCP) [123] 
(which indirectly inhibits angiogenesis) and non-osteoinductive [103,123].
Calcium Sulfate Salt (Plaster of Paris). Plaster of Paris, 
CaSO^VShfeO, was first used in 1892 by Dreesman to treat osteomyelitis 
[32,126,137]. The function of plaster of Paris was to occupy the infrabony 
environment, acting as a scaffolding device and preventing epithelial invagination 
until resorption takes place [3,32], it can be used in the presence of infection with 
no ill effects [123,126]. Plaster of Paris is biologically inert [32,125,126], has a 
resorption rate similar to the growth rate of new bone [26] and is completely 
resorbed [26,125,126], however high turnover and high resorption rate has also 
been reported [8,28]. This difference in results can be attributed to the form of 
plaster of Paris tested, defect size, defect location (loaded or unloaded) and 
quality of plaster of Paris used. Damien and Parsons reported the use of plaster 
of Paris as a good drug delivery system especially for antibiotics [32], indirectly, 
plaster of Paris promotes bone formation. Osteoblasts adhere to plaster of Paris 
and osteoclasts absorb the calcium sulfate, absorption is associated with a large
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osteoclasts, facilitates bone formation [13,26], Plaster of Paris does not 
stimulate osteogenesis [32,136] nor does it inhibit bone formation [126], Strocchi 
et al. reported improved angiogenesis. Calcium sulfate increased the growth of 
microvessels in the defect site compared to unfilled defects [151]. Plaster of 
Paris usage can lead to a slight elevation in serum calcium and alkaline 
phosphate levels [32], which can be overcome with extra water consumption. 
Rush, Laurencin and Khan reported calcium sulfate as brittle and unable to resist 
compressive loads [86,137]. To overcome this, defects filled with plaster of Paris 
must have internal or external fixation.
Chitosan. Chitin is a naturally occurring linear polysaccharide found in 
fungi, yeast, invertebrates, shellfish and crustaceans [90,111,114,135,146]. 
Chitin, composed predominately of poly [0-(1 ->4)-2-acetamido-2-deoxy-D- 
glucopyranosej [40,56,97,135], is the second most abundant natural 
polysaccharide, following cellulose and annual production is estimated to be 
101°-1011 tons [45]. Chitosan, composed of p (1-*4) linked 2-acetamido-2- 
deoxy-0-D-glucose (N-acetylglucosamine), is a derivative of chitin, first 
discovered by Rouget in 1859 [90,135], formed by removal of an acetyl group. 
Deacetylation is accomplished by either enzymatic or alkaline hydrolysis. Chitin 
with a degree of deacetylation of 75% or higher is considered chitosan [83,143]. 
Deacetylation creates chemically active amine groups which give chitosan a 
positive charge. This positive charge allows chitosan to possess functional 
properties [20,24,40,56,90,97,128,129,146]. Functional characteristics range
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from biocompatibility to hypercholesterolemia to anti-tumor properties. The 
positive charge is due to protonation, addition of a H+ which occurs below pH 5 
[49], of a NH2+ group located at the C2 position on the chitin molecule [40], 
therefore charge density is pH dependent [49]. The degree of functional 
properties is dependent on level of deacetylation (charge percentage) [158]. 
Chitin contains two hydroxyl groups while chitosan contains one amino group 
and two hydroxyl groups in a repeating hexoamine residue [84], The structures 
of chitin and chitosan are shown in Figures 1 and 2.
c h 2o h CH?OH
PH
H NHCCH
O
PH
H NHCCH
Figure 1. Chitin molecule.
CH?OH
PH
.+H NH
CH2OH
O
PH
+H NH
Figure 2. Chitosan molecule.
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In addition to chemically active amine groups, chitosan is more readily 
soluble in dilute acids. Chitin is insoluble in water, dilute aqueous salt solutions 
and most organic solvents [111]. Chitosan’s increased solubility, along with 
reactivity, causes chitosan to have more functionality in biomedical applications.
Chitin is found in three forms: a-chitin, (3-chitin, and y-chitin. a-chitin 
consists of anti-parallel chains ( t it )  [85,135,152] and is found primarily in 
arthropods and crustaceans [152]. (3-chitin is comprised of parallel chains ( f t t )  
[85,135,152] and is found in marine diatoms and squid pens [152]. y-chitin 
consists of two parallel chains and one anti-parallel chain ( t t i )  [135,152] and has 
been reported in the past, but its existence is controversial [152]. Chitin is 
present in highest concentrations in the shell of crustaceans. Crustacean shells 
consist mainly of 30-40% protein, 30-50% minerals (mostly in the form of calcium 
carbonate), and 20-30% a-chitin [46]. Chitosan is an excellent source of 
nitrogen, containing approximately 6.89% [84], in the form of primary aliphatic 
amino groups [84]. According to No and Meyers, crawfish chitin contains 7.01% 
nitrogen on a moisture-free, ash-free basis [111]. Chitin is a major source of 
surface pollution [41,42,48,56,85] therefore recycling is environmentally 
beneficial.
Extraction from Crawfish Shells (Procambarus clarkii)
Chitosan is the deacetylated derivative of chitin. General extraction 
process for chitin is removal of proteins and minerals from crawfish shells. 
Deproteinization, removal of proteins, is accomplished by treating ground 
crawfish shells in a dilute sodium hydroxide solution, 3.5% w/v, at an elevated
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temperature, 65-100°C. All proteins are removed in a two hour time period 
[29,46,56,111,113,114]. Demineralization, removal of minerals, is accomplished 
by submerging deproteinated shells in a dilute solution of 1N hydrochloric acid, at 
room temperature for 2-3 hours with agitation [46,111,113,114]. Following 
deproteinization and demineralization, the extracted product is chitin. Chitin is 
converted into chitosan by removal of acetyl groups; this is accomplished by 
submerging chitin in a concentrated sodium hydroxide or potassium hydroxide 
solution, 50% w/v, at elevated temperature, ~100°C. Degree of deacetylation 
increased rapidly during the first hour and slowed afterward [46,159]. Treatment 
beyond two hours does not deacetylate significantly and has been found to 
cause polymer degradation [100,111,114,144,152]. It should be noted that a 
small amount of deacetylation occurs during chitin extraction [111]. Rinaudo, 
Milas and Desbrieres reported a convenient way to achieve a high level of 
deacetylation as 5% w/v of sodium hydroxide at 100°C for three hours [134]. The 
volume of chitosan extracted varies according to order of steps, Femandez-Kim 
reported high yield with demineralization, deproteinization and deacetylation [46].
Chitosan Characterization 
Functional properties of chitosan are due to polycationic nature, charge 
density, which is directly proportional to degree of deacetylation (i.e. the higher 
degree of deacetylation, the more free amine groups and higher the charge 
density) and degradation. Chitosan is degraded by enzymatic hydrolysis 
resulting in oligosaccharides of variable lengths [18,20,35,40,49,83,106,152,162]. 
Highly deacetylated forms of chitosan exhibit the lowest degradation rates [49].
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Since level of deacetylation is important in defining chitosan’s functional 
properties, it is essential to have the ability to measure the level of deacetylation. 
Several different methods have been employed.
Fourier Transform Infrared Spectroscopy
Fourier transform infrared spectroscopy (FTIR) passes a known 
wavelength of infrared light through a sample and records the amount of energy 
absorbed by the molecule. FTIR has been used to determine level of 
deacetylation {38,92] of chitosan, weakening of spectra occurring at 1665 cm'1 
(amide I) is associated with deacetylation [21,34,127].
1H Nuclear Magnetic Resonance Spectroscopy
1H nuclear magnetic resonance spectroscopy (NMR) aligns protons with 
intrinsic magnetic moments with a very powerful external magnetic field and 
perturbs the alignment using an electromagnetic field. The perturbations are 
measured and recorded. All nuclei with odd numbers of protons and some with 
even number of protons have intrinsic magnetic moments, 1H and i3C are most 
widely used. 1H NMR has been used to determine the degree of deacetylation of 
chitosan [47,57,60,67,88,132] as part of chemical characterization [134]. 
Although, Domard and Rinaudo reported that 1H NMR may not be sensitive for 
low acetyl concentration [34].
Differential Scanning Calorimetry
In differential scanning calorimetry (DSC), differences in amount of heat 
required to increase the temperature of a sample and a reference are measured 
as a function of temperature. During melting, more heat is flowing to the sample,
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this is an endothermic reaction. During crystallization, less heat is required to 
raise the temperature (less heat is flowing to the sample), this is an exothermic 
reaction. DSC measures the amount of energy absorbed or released. DSC has 
been used to characterize chitosan [79,81]. Different values have been reported 
for the location of endothermic peaks. Agnihotri and Aminabhavi reported pure 
chitosan having an endothermic peak at 53°C [2], while Dong et al. reported a 
single endothermic peak occurring at 100°C [36]. A range of endothermic peak 
locations, ~35°C-160°C, reported by Cervera et al. and Ratto and Hatakeyama 
[19,131], was attributed to water loss. In addition to water loss, different reported 
temperatures can be attributed to different chitosan extraction techniques, 
different chitosan sources, level of deacetylation and purity. Chitosan is 
amorphous, it lacks crystalline form, when only one peak between 35°C - 160°C 
is present [19]. Exothermic peaks were seen between 280°C and 300°C [19]. 
Cardenas and Miranda reported that as the level of deacetylation increases, the 
decomposition temperature decreases [17]. The samples with high degrees of 
deacetylation will have decomposition temperature approaching 313°C, based on 
92% deacetylated chitosan. Dong et al. reported chitosan having a glass 
transition (Tg) temperature between 140°C-150°C [36]. Glass transition 
temperature is the temperature at which molecules have little or no mobility, 
below the Tg the material is in “glassy” state and above Tg the material is in 
“rubbery” state. In “glassy” state the material is brittle and hard, and in “rubbery” 
state the material is soft and flexible.
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Chitosan Properties
Biocompatibilitv
Chitosan has demonstrated biocompatibility in multiple studies. in vivo, 
chitosan has elicited no pathological inflammatory responses [120], no 
abnormalities were seen in radiographs where chitosan was incorporated as a 
bone graft component [76] and chitosan elicited no signs of necrosis or 
degeneration [76] when used as part of a bone graft. Chitosan demonstrated a 
very low incidence of chitosan-specific reactions [120]. Rao and Hatakeyama 
reported the non-toxic nature of chitosan, acute systemic toxicity tests with 
chitosan in mice did not demonstrate any toxic effects [130]. Chitosan has been 
used to reduce toxicity of positively charged liposomes [45].
Antibacterial Properties
Chitosan possesses antibacterial and antimycotic properties. Interactions 
between positive charge of the chitosan molecule and negative charge of a 
bacterial cell wall lead to altered cell permeability. This altered permeability 
prevents transport of essential nutrients into the cell and results in leakage of 
proteinaceous and other intracellular components [22,24,145,146]. Chitosan 
inhibits bacterial proliferation independent of the bacterial charge, both gram- 
negative and gram-positive bacteria are inhibited [112,115,129] although the 
antibacterial effect was greater with gram negative bacteria [22,33]. Antibacterial 
efficacy is dictated by degree of deacetylation, pH and temperature. As degree 
of deacetylation increases, antibacterial effect increases [22,33,44,144]. The 
same correlation is observed with temperature. As temperature increases, the 
antibacterial efficiency increases [24]. An inverse relation is observed with pH,
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antimicrobial efficiency increases as pH decreases [74,112]. Chitosan in media
with a pH of 7.0 or greater demonstrated no antimicrobial activity [44,162]. Only
small amounts of chitosan were required to inhibit bacterial growth. Kumar
determined growth of Escherichia coli was inhibited in a solution with as little as
0.025% chitosan [84]. Jumma reported lipid emulsion prepared with chitosan
demonstrated antimycotic properties [74].
Haemostatic and Anticoagulant 
Properties
Chitosan has demonstrated haemostatic and anticoagulant properties 
[18,84,106]. Native chitosan promotes haemostasis while chitosan coupled with 
sulfur acts as an anticoagulant [90]. Okamoto et al.. worked on haemostatic 
properties of chitosan, determining that blood coagulation time varied 
significantly in a dose-dependent manner [118] and chitosan was found to be a 
superior haemostatic agent compared to chitin [118]. Chitosan causes blood 
coagulation by influencing platelets to form a clot [83,118], and significantly 
increases platelet adhesion [27]. Chitosan promotes blood coagulation in very 
low concentrations [130]. Fradet et al. reported the effective use of chitosan as a 
haemostatic agent under severe anticoagulation conditions [48], however Kind 
reported the ineffective use of chitosan as a topically applied haemostatic agent 
for liver laceration compared to pressure alone [80]. Difference in chitosan 
functionality is possibly due to the level of deacetylation, chitosan source, 
preparation procedure and interactions with medicinal compounds; none of which 
were discussed.
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Wound Healing
Chitosan has been shown to possess wound healing properties [83] that 
accelerate healing by approximately 75% [41,42]. Chitosan treated wounds 
generated normal tissue elements, no visible scaring was observed at the wound 
surface [96]. This is due to chitosan’s ability to inhibit fibroplasia 
[20,40,41,82,84,96,157]. Attempts to grow fibroblasts in media containing 
chitosan resulted in rounding up of cells, extension of short processes, inability to 
lay down and eventually cell death [96]. In addition to fibroplasia inhibition, 
chitosan and chitin have been shown to cause release of type I collagenase from 
fibroblasts [119]. During the final stages of wound healing, granulation tissue is 
degraded by enzymes, such as type I collagenase, and remodeled [119]. Early 
release of type I collagenase results in early degradation of granulation tissue 
and remodeling leading to decreased scar formation. In addition to inhibiting 
fibroplasia, chitosan accelerates wound healing by accelerating the infiltration of 
inflammatory cells and migration of polymorphonuclear cells [157]. Based on 
chitosan’s superior ability to accelerate wound healing, several wound dressing 
materials are being tested. Chitosan wound dressings have been shown to 
possess the ability to control bacterial growth [40,75,78,102], perform 
haemostatic functions [144] and increase the proliferation of human F1000 
fibroblasts [45]. Chitosan possesses natural anti-bacterial, haemostatic and 
analgesic properties. Chitosan bandages were shown to stop bleeding at a rate 
of 600 milliliters per minute [144]. The difference in ability of chitosan to inhibit 
fibroplasia or promote fibroblast proliferation can be attributed to several factors,
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such as: degree of deacetylation, chitosan source, molecular weight and method 
of production. These factors are omitted in the literature and lead to differences 
in reported results, which has resulted in chitosan’s slow progression as a 
biomaterial. On skin, chitosan was reported to promote production of keratin [83] 
resulting in decreased scar formation. A chitosan conjugate, N-carboxybuty! 
chitosan, was shown to favor formation of loose connective tissue rather than 
dense fiber bundles [11]. Angiogenesis plays an important role in wound healing 
by re-supplying blood to affected areas. Re-vascularization allows cells to 
proliferate and repair to continue. Chitosan has demonstrated angiogenesis 
promotion during wound healing [83], Okamoto et al. demonstrated the ability of 
chitosan to reduce inflammatory pain [117]. Chitosan’s wound healing ability, 
angiogenic, analgesic and antibacterial capabilities make it suitable for artificial 
skin. Kumar et al. demonstrated superior healing with artificial skin composed of 
chitosan [83] and wound healing is accelerated by chitosan oligomers released 
upon degradation [84]. Chandy reported accelerated healing and healed skin 
surface with chitosan artificial skin [20]. Chitosan films have been developed into 
artificial kidney membranes [39]. Due to charge on the chitosan molecule, 
artificial kidney membranes containing chitosan demonstrated high tensile 
strength and suitable permeability [40,41,106]. Orally administered chitosan has 
been shown as a treatment for renal failure. Taken orally, chitosan significantly 
reduces creatinine and serum urea levels [146]. Chitosan films were shown to 
turn more hydrophobic when sterilization was accomplished through autoclaving 
[130]. Increased hydrophobicity improves chitosan’s film and gel forming
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capabilities. Gel modification with alginate resulted in increased hydrophilicity, 
increase in hydrophilicity is proportional to the volume of alginate added [65],
Druo Delivery
Chitosan has demonstrated drug delivery capabilities. Gupta and Kumar
reported the use of chitosan as part of a transdermal drug delivery system
[56,83,84]. Oral [77,83], nasal [83] and ophthalmic preparations [83] of chitosan
have been prepared for drug delivery. Formulations containing chitosan have
been used for control release [39,40,41,45,75,84,146] and as a hydrophilic drug
absorption enhancer across intestinal and nasal mucosa [146]. Microspheres
and nanoparticles have been developed with chitosan for mucosal drug delivery
[163] and as hydrophobic drug carriers [2,78]. Degradation rate of chitosan has
important implications on drug delivery capabilities, the larger the particle size
and the higher the degree of deacetylation, the longer the degradation rate
[51,68,78,162]. Particle size can be controlled by varying amounts of chitosan
within the particle [72].
Anti-Tumor and Anti-Viral 
Characteristics
Chitosan, along with chitosan conjugates, have demonstrated anti-tumor 
and anti-viral properties. Chitosan inhibits viral infection in animal cells [128] and 
stimulates immune response to viral antigens [129]. Shahidi reported chitosan’s 
role as an inhibitor of tumor cell growth [144]. Several chitosan conjugates have 
been reported as demonstrating anti-tumor properties. Water-soluble N-succinyl- 
chitosan-mitomycin C conjugates [75], 6-0-carboxymethyl-chitin [138] and 
chitosan conjugates of 5-fluoro uracil [45] have demonstrated anti-tumor activity.
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Anti-tumor activity can be attributed to malignant cells possessing a net 
electronegative surface charge that interacts with chitosan’s polycationic surface 
charge [106]. Kato et al. reported use of chitosan nanoparticles as part of 
gadopentetic neutron capture therapy for cancer treatment [75], Concentration of 
gadolinium in melanoma tissue in mice was approximately 74% of the original 
dose contained in an intratumoral injection of gadolinium-chitosan nanoparticles, 
compared to only 0.7% of the original dose when administered in a dimeglumine 
gadopentetate solution.
Nerve Cell Regeneration
Chitosan possesses possible nerve cell regeneration properties. Patel et
al. reported on chitosan’s ability to accelerate nerve growth and repair [124].
Researchers reported chitosan’s high affinity for nerve cells [69,165], this is due
to the polycationic nature of chitosan. Kumar et al. reported on the ability of
chitosan to cause PC12 cells to extend neurites upon exposure to nerve growth
factor [83]. PC12 cells are from a well characterized cell line derived from
transplantable rat adrenal pheochromocytoma. PC 12 cells respond reversibly to
nerve growth factors. Freier et al. developed chitin-based tubes for neuronal
support [50]. Chitosan-based tubes were compared to chitin-based tubes and
found to have higher mechanical strength and higher nerve cell affinity than
chitin-based tubes.
Dietary and Hvpocholesterolemic 
Properties
Chitosan has been shown to possess dietary and hypocholesterolemic 
properties. This is an area of controversy as opposing results have been
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reported. NiMhurchu et al. reported marginally greater weight loss with chitosan 
treatment combined with lifestyle and dietary change in 250 patients [110] while 
Kumar reports no change in body weight with chitosan treatment, unspecified 
number of patients [83]. These differences can be attributed to molecular weight, 
production method, degree of deacetylation, chitosan source and sample size. 
Chitosan binds to fat in the stomach before digestion trapping the fat and 
preventing absorption in the digestive tract [39,84,144,146]. Binding is due to the 
polycationic nature of chitosan and anionic nature of fat molecules. Since fat is 
not absorbed, chitosan intake increases fecal fat excretion and significantly 
decreases total serum cholesterol [83,146].
Tissue Engineering
Cartilage Tissue Engineering. Chitosan demonstrated superior 
performance in cartilage tissue engineering. Iwasaki et al. reported alginate- 
chitosan scaffolds enhanced biological responses of seeded chondrocytes in 
vitro, including enhanced cell attachment and cellular proliferation [70]. Chitosan 
concentration was found to smooth scaffold surface. Increasing chitosan 
concentration resulted in smoothing of the alginate-chitosan scaffold surface [70]. 
DiMartino and Risbud described chondrocytes cultured on chitosan sulfate 
scaffolds as maintaining round morphology and exhibiting preserved synthesis of 
extracellular matrix [1]. Chitosan sulfate hybrid polymer fibers exhibited 
increased cellular attachment and proliferation in vitro compared to alginate [1]. 
Kumar reported chitosan promotion of chondrocyte attachment and extracellular 
matrix synthesis [83]. Hoemann et al. measured PCNA (proliferating cell nuclear
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antigen) expression and increased cell density to determine increased 
proliferation of chondrocytes due to chitosan exposure [61]. A combination of 
chitosan/GP (disodium p-glyceroi phosphate) blood solution improved quantity 
and quality of cartilage repair [62].
Bone Tissue Engineering. Chitosan demonstrated potential in bone tissue 
engineering. Chitosan demonstrated osteoconductive properties [72]. In culture, 
chitosan sulfate promoted mineral deposition and growth by osteoblasts [1]. 
Borah, Scott and Wortham reported induction of bone growth in chitosan treated 
defects [12]. Calcification was observed on chitosan membranes after seven 
days [10], this calcification was the same observed with apatites [10], the major 
mineral in bone being hydroxyapatite. Bone defects treated with chitosan 
demonstrated increased calcification at increasing time intervals [12], Chitosan 
sponges seeded with osteoblasts produced mineralized tissues [142]. Chitosan 
supported initial attachment and spreading of osteoblasts [43] and had an 
inhibitory effect on fibroblast cell attachment [82], this inhibitory effect leads to 
decreased scar formation. In addition to an inhibitory effect on fibroblasts, 
Fakhry et al. reported preferential initial attachment and spreading of osteoblasts 
over fibroblasts [43]. The characteristic of chitosan to promote adhesion of 
osteoblasts is governed by the degree of deacetylation. Cellular adhesion 
increases as level of deacetylation increases [14,40,51,65,128]. Hu et al. tested 
nanocomposite rods composed of chitosan and hydroxyapatite for internal 
fixation of bone [66]. Chitosan/HA nanocomposite rods were found to possess 
high bending strength and high modulus of elasticity. Addition of hydroxyapatite
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increased bending strength, compared to chitosan, but lowered the elastic 
modulus [66], Increased elasticity is due to water absorbed by the chitosan 
component of the nanocomposite rods. A chitosan/hydroxyapatite paste was 
tested by several groups and reported to be osteoconductive [68,78] as well as a 
suitable osteoblast cell delivery system [105], McCord, Spence and Hudson 
reported on chitosan/hydroxyapatite paste as having superior tensile modulus 
and comparable tensile strength to bone, along with the ability to self-harden. 
However, chitosan/hydroxyapatite paste demonstrated inferior shear strength 
[101]. Cho et al. reported on the use of a chitosan/calcium sulfate composite as 
a bone graft and observed significant bone formation in defect, compared to a 
control group [25]. This combination was found to promote early bone formation 
and decrease the period of bony consolidation [26], activate macrophages and 
mononuclear cells and induce production of fibroblast growth factor and platelet 
derived growth factor [26]. After six weeks, histological examination showed 
nearly normal cortical bone [25J. Mallette, Quigley and Adickes reported defects 
treated with chitosan formed cortical bone, while control defects exhibited classic 
osteoblastic-osteoclastic sequence [96]. Klokkevold et al. demonstrated 
chitosan’s ability to enhance osteogenesis. Chitosan doubled the number of 
osteoblast colonies in vitro [82]. DiMartino and Risbud reported on chitosan’s 
ability to bind with growth factors, making chitosan suitable for bone engineering 
[1]. Incorporation of chitosan nanoparticles into bone cements provides effective 
antibacterial action [145]. Ceil proliferation and tissue organization is 
strengthened and accelerated by presence of host stromal matrix along with the
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chitosan macromolecule [107]. As a potential treatment of osteoporosis, Li et al. 
demonstrated that low molecular weight chitosan inhibits formation of osteoclast­
like muitinucleated cells and inhibits bone resorbing activity in vitro [89]. 
Osteoporosis occurs when bone absorption exceeds formation.
Scaffolds for Tissue Engineering. Scaffolds composed of chitosan have 
been tested for several different applications. Pan et al. reported using chitosan 
scaffolding as a support for hepatocytes [122]. Chitosan scaffolds have been 
developed as blood vessel supports due to chitosan’s ability to form scaffolds 
with pore sizes approximately 50 to 150 micrometers, its ability to withstand 
maximum pressures of 4300 mmHg and enable rapid proliferation of blood 
vessel epithelial cells [164]. Properties of tubular blood vessel scaffold varied 
according to the temperature under which the film was formed [164]. A 
scaffolding sponge containing chitosan suitable for bone tissue engineering was 
reported on by Seol et al. [142]. The chitosan bone sponge possesses a pore 
size of approximately 100 to 200 micrometers and demonstrated accelerated 
osteoblast proliferation. Pore sizes of approximately 100 micrometers are 
necessary for bone growth. Li et al. tested collagen based scaffolds reinforced 
with chitosan for bone tissue engineering [91]. The pore sizes in the collagen- 
chitosan scaffold were approximately 100 to 200 micrometers, ideal for 
proliferation of bone tissue. By increasing the volume of chitosan fibers, Li et al. 
demonstrated an increased compressive strength, but an increase in fiber length 
caused a decrease in scaffold porosity [91]. Tan and associates developed 3-D 
gel scaffolding composed of collagen and chitosan. Chitosan concentration
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greatly influenced pore size [153] and gel viscosity [153], the viscosity increased 
proportionally to chitosan concentration. Tan et al. reported chitosan affects cell 
proliferation but does not significantly affect cell viability [153].
Commercial Products
Therapeutic contact lenses [45] containing chitosan were reported by 
Felse. Chitosan contact lenses demonstrated a higher permeability to oxygen 
compared to conventional lenses [39,40,41]. Felse and Panda reported the use 
of chitosan as supporting material for implantable glucose biosensors [45]. Chitin 
has been used in the production of sutures due to its ability to resist degradation 
in bile, urine and pancreatic fluids [41,84]. Romoren et al. reported on the long 
term storage of chitosan. Chitosan maintains in vitro transfection efficiency and 
physiochemical properties for over a year when stored at 4°C [136], Chitosan 
has been successfully used in cosmetics [39,40,56,75,85]. Along with chitosan’s 
natural antimicrobial properties, chitosan’s polycationic nature naturally attracts 
to skin and hair. In wastewater industry, chitosan has demonstrated metal 
chelating properties by binding various metal ions [39,45,56,84,92,129], it has 
been used to collect and remove trace amounts of metal ions in river water 
samples [39]. In photography, chitosan has been found to be a suitable fixing 
agent [39,40,41,56,84]. In paint manufacturing, chitosan is used as a thickening 
agent [39]. In the paper industry, chitosan is used in paper finishing and as a 
surface treatment on photographic and carbonless copy paper [39,40,56,84,90]. 
In textile industry, chitosan is used in dye chelation, removing dyes from dye 
processing effluents [39,45,84] and to impart antistatic and soil repellent
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characteristics to textiles [40]. in agriculture, chitosan was found to have growth 
accelerating and growth enhancing effects on wheat seeds [40]. Chitosan has 
good emulsifying properties, it is used in the food industry [40,56,84,90] for 
thickening and gel-forming [39].
Bone Biology
Bone is composed of two types of tissue: cortical and cancellous. Cortical 
bone is dense and surrounds cancellous bone, thickness varies by location, 
thicker layers are found surrounding bones under stress (load bearing), such as 
a femur or humerus. Cancellous bone is internal, to cortical, and contains 
trabeculae with void (empty space), with much higher surface area than cortical. 
All bones are composed of cells and a complex matrix consisting of organic and 
inorganic components. Three types of cells are present in bone: osteoblasts, 
osteocytes and osteoclasts. These cells are responsible for bone production, 
maintenance and resorption, respectively. Bone matrix is composed of organic 
and inorganic components. The organic component consists of 95% collagen, 
mainly Type I with some Type V, with the remainder being non-collagenous 
proteins; osteocalcin, bone sialoprotein, osteopontin and osteonectin. The 
inorganic portion of the matrix is composed of calcium and phosphate salts. The 
location of cortical and cancellous bone in the femoral head is in Figure 3.
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Figure 3. Structure of cortical and cancellous bone [58].
Ossification
Bone formation occurs following two different pathways: intramembranous 
and endochondral. Intramembranous ossification is direct differentiation of 
mesenchymal cells into osteoblasts and is responsible for development of flat 
bones (i.e. skull). Endochondral ossification is differentiation of mesenchymal 
cells into chondrocytes, which are replaced by osteoblasts and is responsible for 
most skeletal development, especially long bones.
Intramembranous Ossification. During intramembranous ossification cells 
derived in the neural crest proliferate and condense into nodules. Some of these 
cells differentiate into osteoblasts, while others form capillaries. Osteoblasts 
secrete a matrix, osteoid, that is capable of mineralization through binding of 
calcium salts. As osteoid is secreted, osteoblasts retreat. Occasionally, an 
osteoblast is trapped in mineralizing osteoid. When this occurs, the osteoblast 
differentiates into an osteocyte. As the osteoid calcifies, spicules are formed that 
radiate out from the point of ossification. These spicules connect and become
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trabeculae of cancellous bone. The surface of the entire area of calcified spicule 
is surrounded by compact mesenchymal cells that develop into periosteum, a 
vascularized membrane that surrounds bone. Cells on the inner surface of the 
periosteum continue to produce matrix. This matrix becomes dense and upon 
calcification forms cortical bone. Bone morphogenic proteins (BMP) are thought 
to orchestrate direct differentiation of mesenchymal cells into osteoblasts. BMPs 
(BMP2, BMP4 and BMP7) activate core binding factor alpha one (Cbfal) gene 
which encodes for Cbfal transcription factor. Cbfal transcription factor activates 
the genes for osteocalcin, osteopontin and other matrix proteins thereby causing 
direct transformation of mesenchymal cells into bone forming cells. Sources for 
mesenchymal cells are the periosteum, intracortical zone, endosteum and bone 
marrow; however hemopoietic cells of the bone marrow make no significant 
contribution to bone formation [15]. Figure 4 shows intramembranous 
ossification diagrammatically.
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Figure 4. Intramembranous ossification [54],
Endochondral Ossification. Endochondral ossification consists of five 
steps (Figure 5):
1. Mesenchymal cells commit to differentiate into chondrocytes. 
Commitment is dictated by paracrine factors that cause nearby 
mesodermal cells to express two transcription factors, Pax1 and 
Scleraxis. Pax1 and Scleraxis are thought to activate cartilage specific 
genes.
2. Condensation of committed mesenchymal cells into nodules. Two 
factors are critical for initiation and maintenance of the nodules, neural 
cell adhesion molecule (N-CAM) and neural cadherin (N-cadherin). N- 
CAM is crucial for initiation of committed mesenchymal cellular 
condensation and N-cadherin is essential for nodule maintenance.
....
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3. Chondrocyte proliferate and form a scaffolding model for bone growth. 
During proliferation, chondrocytes secrete cartilage-specific matrix.
4. After cells form the shape of the bone, proliferation ceases and 
chondrocytes undergo hypertrophy. In hypertrophy, chondrocytes stop 
dividing and increase volume. The hypertrophic chondrocytes secrete 
collagen type X and fibronectin, which allows the matrix to bind calcium 
carbonate and become mineralized.
5. Angiogenesis (blood vessel growth and invasion) occurs within the 
cartilage model and hypertrophic chondrocytes undergo apoptosis. 
New bone formation or repair must always be preceded by formation of 
a vascular network. As apoptosis occurs, cells surrounding the 
cartilage model will differentiate into osteoblasts. These osteoblasts 
will secrete a bone specific matrix directly on the cartilaginous matrix.
Endochondral ossification begins in the future location of the middle of the bone 
and spreads outward.
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Figure 5. Endochondral ossification [54].
Bone Resorption
Bone resorption is performed by specialized cells called osteoclasts. 
Osteoclasts are specialized multinucleated macrophages [58,155] that dissolve 
bone into constituent components. Resorption occurs naturally as a mechanism 
of maintenance, whereby stress fractures cause release of alkaline phosphatase 
leading to a change in pH. The change in pH recruits macrophages (osteoclasts) 
to the site to remove debris. Osteoclasts, Figure 6, possess a specialized 
cytoskeleton that permit establishment of an isolated microenvironment between 
itself and debris (bone). Bone matrix is demineralized by a process involving 
proton transport which causes acidification of the isolated microenvironment 
[155]. The quantity of bone resorbed is dictated by expression of 
osteoclastogenesis stimulator (RANK) and an inhibitor (OPG) [155].
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Figure 6. Scanning electron micrograph, osteoclast (Univ. of Oulu).
Bone Repair
Bone repair occurs through endochondral ossification. Bone is the only 
tissue that is repaired with formation of new bone; all other tissue is repaired with 
connective tissue [58]. Repair endochondral ossification is similar to molecular 
and cellular patterns seen in embryonic endochondral ossification. Local method 
of repair is dependent on blood supply. Complete repair is by endochondral 
ossification but local osteoprogenitor cells that are in contact with a good blood 
supply differentiate directly into osteoblasts. Angiogenesis plays a major role in 
the method of repair.
Bone repair occurs following the events [54] listed:
1. A haematoma forms due to damage to the periosteum (a nutrient- 
supplying vascularized membrane surrounding bone) and local tissue.
2. The interruption of blood supply causes local tissue necrosis, due to 
hypoxic conditions.
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3. Macrophages and fibroblasts are recruited to the area. The 
macrophages remove debris and the fibroblasts secrete extracellular 
matrix. Mauney et al. proposed the recruitment of macrophages and 
fibroblasts are caused by a local change in pH due to release of 
alkaline phosphatase caused by mechanostimulation [99], 
Macrophages and fibroblasts release growth factors and cytokines 
which recruit mesenchymal cells from the periosteum and bone 
marrow. Mesenchymal cells proliferate and differentiate into 
osteoprogenitor cells (precursors to osteoblasts).
4. Cellular proliferation causes the periosteum to thicken and formation of 
fracture callus around fracture site. Osteoprogenitor cells that are 
close to undamaged bone, good blood supply, directly differentiate into 
osteoblasts. These osteoblasts quickly form osteoid which is 
mineralized into bone. Cells farther away from a vessel, hypoxic 
conditions, differentiate into chondrocytes and form cartilage, which 
stabilizes the fracture and allows angiogenesis to occur. In 
mechanically stable bone, bone formation occurs by intramembranous 
ossification. In mechanically unstable bone, angiogenesis cannot take 
place and avascular tissue, cartilage, is laid down to stabilize the 
fracture. Once the fracture is stabilized, cartilage is replaced by bone 
[5,54].
5. Following angiogenesis, new bone is deposited on the cartilaginous 
matrix.
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Graft Incorporation
Following graft implantation, normal processes immediately initiate 
incorporation by endochondral ossification. While specific details differ between 
different grafting materials, general principles are the same. The graft is used as 
scaffolding, osteoconduction, whereby chondrocytes lay down cartilage which 
undergo hypertrophy and are invaded by osteoblasts. Osteoblasts lay down 
bone and are followed by osteoclasts which remodel bone and remove the graft.
Graft incorporation begins with formation of a haematoma at implantation 
site [9,133]. The haematoma releases cytokines and growth factors which begin 
the ossification cascade [9]. Within minutes of graft implantation, platelets are 
released [133]. The release of platelets, leads to recruitment of 
polymorphonuclear leukocytes (PMN) by chemotaxis, this takes approximately 
one hour post-implantation [133]. Over the next three to eighteen hours, PMNs 
accumulate and adhere together [133]. Adhesion of PMNs cause recruitment of 
fibroblasts, by chemotaxis, and fibroblast attachment to the implanted graft, this 
occurs approximately one day post-implantation [133]. For the next day, day 
two, chemotaxis for fibroblasts and attachment of fibroblasts to the graft 
continues [133], this is osteoconduction. On the third day, cells on the implanted 
matrix proliferate and signal transduction occurs from the implanted matrix to 
fibroblast cell surface [133]. Signal transduction causes differentiation of 
chondroblasts into chondrocytes during the fourth and fifth days, this is 
osteoinduction. Chondroblasts are mesenchymal stem cells recruited from 
periosteum, intracortical zone, endosteum and/or bone marrow that are
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committed to differentiating into chondrocytes. During the next two days, day six 
and seven, chondrocytes synthesize and secrete cartilage specific extracellular 
matrix [133]. Following differentiation, chondrocytes undergo hypertrophy, 
cartilage matrix mineralizes and angiogenesis takes place [133], day nine. 
Angiogenesis occurs via existing Haversian and Volkmann canals [9]. During 
days ten and twelve, mesenchymal stem cells surrounding the graft differentiate 
into osteoblasts, which synthesize and secrete bone matrix [133]. Following 
secretion of bone matrix, local macrophages differentiate into a multinucleated 
osteoclast. During days twelve through eighteen, osteoclasts remodel and 
dissolve the implanted bone graft [133]. Following remodeling, bone marrow 
differentiates and the graft is completely dissolved [133].
Discussion of the Literature 
Chitosan is biocompatible, antibacterial, antifungal, haemostatic, antiviral, 
non-toxic and osteoconductive. It has demonstrated scar reduction properties. 
The degradation rate can be manipulated and it can be used as a drug delivery 
vehicle as well as a delivery vehicle for growth factors. Chitosan has 
demonstrated wound healing abilities and analgesic properties along with 
promoting osteogenesis. Chitosan is not structurally supportive, grafted bone 
must be stabilized with internal or external fixation, and will only dissolve in an 
acidic solution, will not form a paste singularly in a neutral pH solution. Chitosan 
has many characteristics that make it a favorable polymer for a bone graft, 
including osteoconduction, drug delivery capabilities, anti-bacterial and anti­
fungal characteristics and haemostatic properties, in addition, chitosan
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possesses a positive charge that enables it to bind with other functional 
compounds thereby expanding its functionality.
Calcium sulfate, plaster of Paris, is biocompatible, able to dissolve in 
neutral pH, non-toxic, and inert. It has successfully been used as filler in boney 
voids for more than one hundred years. It is resorbed quickly and completely 
and can be used as a drug delivery vehicle. Calcium sulfate can be used in the 
presence of osteomyelitis and absorption is associated with large numbers of 
osteoclasts, which indirectly promotes bone formation. Calcium sulfate has been 
proposed to promote angiogenesis. Calcium sulfate is not structurally 
supportive, grafted bone must be supported with either internal or external 
fixation, nor will it promote osteogenesis.
Bone grafting is the traditional treatment for bone loss due to 
musculoskeletal trauma or metabolic diseases. Autografts are in limited supply 
and subject the patient to additional risks of infection and pain. Allografts are 
also limited in supply and subject the patient to increased risks of immune 
reaction and disease. Therefore, development of synthetic bone graft materials is 
an active area of research. Ideally a bone graft should be osteoconductive, 
osteoinductive and osteogenic. Currently available bone grafts possess one or 
two of these characteristics but none possess all three. By combining crawfish 
chitosan, plaster of Paris and osteoblasts this study aims to develop a bone graft 
that possesses all three characteristics.
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Hypothesis
Ideally a bone graft is osteoconductive, osteoinductive and osteogenic. It 
should be able to repair a defect with its constituent components as well as 
support osteoblast proliferation and recruit mesenchymal cells from the 
surrounding tissue to continue the reparative process. Synthetic bone grafts 
currently available perform one or two of these functions.
The long-term purpose of this study is development of a synthetic bone 
graft which is osteoconductive, osteoinductive and osteogenic. The general 
hypothesis is that a combination of crawfish chitosan, plaster of Paris and 
cultured osteoblasts will have all three of these properties. The graft would be 
osteoconductive, as chitosan and plaster of Paris have demonstrated 
osteoconductive properties [3, 32, 72]. Osteoblasts would provide the cellular 
basis for matrix deposition [15], and plaster of Paris would promote angiogenesis 
[151], which in turn would facilitate bone repair. In addition, plaster of Paris 
indirectly recruits macrophages (osteoclasts) [125]. Absorption of plaster of Paris 
is associated with a large number of osteoclasts which release growth factors 
and cytokines, recruiting mesenchymal cells. The graft function can be detected 
through decalcified histology sections, undecalcified histology sections, 
mechanical testing and microcomputed tomography. Specific hypotheses will be 
based on a comparison of experiments on two sets of defected bones, one 
containing the crawfish chitosan bone graft and the other containing no graft. 
Bone is composed of organic and inorganic components, 95% of the dry weight 
of bone is due to collagen fibers (organic) and bone mineral crystals (inorganic).
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Decalcified histology sections will be stained with Hematoxylin and Eosin. 
Hematoxylin is a basophilic dye and Eosin is an acidophilic dye. Eosin will bind 
to collagen because of its acidic nature. Undecalcified histology sections will be 
stained with a Goldners’ Trichrome. Light green stain is a component of 
Goldners' Trichrome stain that dyes collagen fibers due to collagens’ acidic 
nature. The first hypothesis is that the presence of the graft material will promote 
the growth of bone, as measured by microcomputed tomography, decalcified 
histology sectioning and undecalcified histology sectioning. The second 
hypothesis is that bone with and without the graft material will have different 
stiffnesses and different fracture loads, as measured with a mechanical loading 
device. The third hypothesis is that the appearance of the defect in three- 
dimensional microcomputed tomography images of the bone will be smaller, both 
internally and externally, for defects that have been treated with the graft 
material. Microcomputed tomography will be used to produce single slice X-ray 
images as well as three dimensional rendered images. This initial investigation 
was designed to evaluate the promise of the material for bone grafts and to direct 
the research toward more definitive tests in the future if such promise is 
demonstrated. Therefore, the testing methodologies were chosen not only for 
their appropriateness to the study of bone grafting, but also for tiieir availability.
Further hypotheses will relate to the properties of the chitosan being 
used, as opposed to the effect of the material on bone growth. Currently 
available commercial grade chitosan contains amorphous and crystalline 
structures. The combination of amorphous and crystalline structures makes
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degradation unpredictable as crystals degrade at a different rate than amorphous 
structures. The crawfish chitosan used in this project was heated then cooled 
rapidly in liquid nitrogen, which is a common practice in creating amorphous 
structures, therefore a fourth hypothesis is that the crawfish chitosan is 
amorphous following heating and rapid cooling. The amorphous nature of the 
material will be characterized with a differential scanning calorimetry, which 
measures the differences in amount of heat required to increase the temperature 
of a sample and a reference.
A fifth hypothesis is that the procedure being used in this study to extract 
crawfish chitosan, which was patented by Dr. Debi Mukherjee, Louisiana Health 
Sciences Center, Shreveport, Louisiana yields a chitosan with a purity similar to 
commercially available medical grade chitosan. Spectra from the extracted 
crawfish chitosan and commercially available chitosan will be compared with two 
techniques, Fourier transform infrared spectroscopy (FTIS) and nuclear magnetic 
resonance spectroscopy (NMRS). Spectral similarities for the two materials will 
be characterized, and characteristic spectra or “fingerprints” of crawfish chitosan 
extracted using Dr. Debi Mukherjee’s procedure will be delineated. Such spectra 
will be useful in later studies, both for quality control and for characterizing the 
relationship between the structure and properties of the exfracted chitosan.
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MATERIALS AND METHODS
Crawfish Chitosan Characterization
Fourier Transform Infrared 
Spectroscopy
Fourier transform infrared spectroscopy (courtesy of Louisiana Tech
University, Ruston, Louisiana) was performed on solid samples using a Nicoiet
Nexus 470 spectroscope with 512 scans per sample and a resolution of 1.
1H Nuclear Magnetic Resonance 
Spectroscopy
Nuclear magnetic resonance spectroscopy (courtesy of Centenary 
College, Shreveport, Louisiana) was preformed on a Bruker Avance 300. 
Sample was prepared for 1H nuclear magnetic resonance spectroscopy per 
published ASTM protocol with 16 scans at 90°C. The nuclear magnetic 
resonance spectroscopy protocol is listed in Appendix A.
Differential Scanning Calorimetry
Differential scanning calorimetry (courtesy of Centenary College, 
Shreveport, Louisiana) was performed on a Perkin Elmer DSC 6 with solid 
samples. The isothermal temperature was 25°C for 3 minutes and the dynamic 
range was 25-400°C at a rate of 10°C/minute with a sample weight of 25 
milligrams.
40
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Surgical Materials and Methods
Surgical Materials
Isoflurane USD (Halocarbon Laboratories), Sunbeam electric shaver 
(model 059750-070-000), 70% ethyl alcohol (Fisher Healthcare), Betadine 
(Purdue Pharma L.P.), four hole titanium plate (cut from a twelve hole oral- 
maxillofacial plate, Synthes Corporation), Dremei tool (Ryobi Corporation, model 
HT20VS), 3.0 absorbable coated vicryl suture (Ethicon), calcium sulfate 
hemihydrate 98% (Aldrich Chemical Company, Inc.), and Polysporin (Pfizer 
Consumer Healthcare).
Osteoblast Cell Culture
Osteoblast cells were cultured from rat femoral bone marrow aspirate to 
an average concentration of 4.06x105/mI, using published protocol [105]. The 
osteoblast cell culture protocol is in Appendix B.
Crawfish Chitosan Extraction
Crawfish chitosan was extracted per patented procedure [104] which 
followed the guideline in Table 1.
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Table 1. Chitosan extraction from crawfish.
Demineralization - remove minerals - room temperature for 2 hours in 1N HCI (1:10 w/v)
Place in 80°C oven for 48 hours
Wash and dry chitin
Purification - dissolve in 2% acetic acid (1:100 w/v), place in 12,000-14,000  
Dalton dialysis membrane for 24 hours
Quench hot shells in liquid nitrogen
Wash and dry chitosan
Deacetylation - remove acetyl groups - 80°C for 96 hours in 50% NaOH (1:10 w/v)
Wash and dry purified chitosan
Deproteination - remove proteins - 65°C  for 2 hours in 3 5% NaOH (1:10 w/v)
Wash and dry shells
Remove carapace, wash with nanpure water and dry in 163°C oven
Crawfish Chitosan Bone 
Graft Preparation
Crawfish chitosan bone graft was prepared by combination of cultured 
osteoblasts, calcium sulfate (plaster of Paris), and crawfish chitosan. The ratio of 
chitosan to calcium sulfate was 1:4, ideally 0.1250g of crawfish chitosan to 
0.5000g calcium sulfate. The actual average paste contents were 0.5104g of 
calcium sulfate and 0.1245g of crawfish chitosan with an average osteoblast
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concentration of 2.30 x 105/ml. The exact measurements of each component are 
listed in Appendix C.
Critical Size Defect Model
A critical defect is a defect which will not heal spontaneously during the 
lifetime of the animal [4,141]. In rats, critical defect size is three to four 
millimeters, in any bone excluding flat bones. Bone grafts are required for the 
repair of critical defects.
Surgical Procedure 
To determine in vivo efficacy of this new chitosan synthetic bone graft a 
critical defect was created on the dorsal surface of the femur of male Lewis Rats, 
approximately two months of age and 200 to 250 grams in weight, per 
Institutional Animal Care and Use Committee (IACUC) protocol #P-04-001 
(detailed in Appendix F). In order to reduce systematic error, the location of the 
defect was randomized from animal to animal. To sedate the animal prior to 
safely moving it to the surgical Table, light anesthesia was administered by 
lowering the animal into a plastic container containing paper towels coated lightly 
in 100% Isoflurane. Once anesthetized the animal was connected to a surgical 
gas administering device capable of administering 5% Isoflurane and oxygen.
All of the animals were oriented dorsal side up. Their limbs were taped 
down and the femoral location was determined by palpitation, Figure 7. The 
animal was shaved and the area was wiped down using 70% alcohol on sterile 
gauze followed by Betadine. An incision was made along the femur beginning at 
the femoral head and continuing the length of the femur.
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Figure 7. Rat in surgical frame.
The incision was held open using a retractor and the muscle was cut in 
the same fashion. AH soft tissue was removed from the femur and the four-hole 
plate was attached, screw holes were drilled with a Dremel tool. Once the plate 
was securely fashioned, a critical defect was created using a 2.5mm burring bit. 
The defect was approximately three millimeters wide and spanned the entire 
width of the femur. In the operated control group, once the defect was created, 
the muscle was sutured, with 3.0 Vicryl coated suture (Ethicon, Inc.). In the 
experimental group, the defect was filled with chitosan bone graft and the muscle 
was sutured. The skin incision was closed using staples. Staples were chosen 
because in previous experiments the animals chewed through sutures. A 
generous application of Polysporin, an antibiotic cream, was applied to the 
exterior of the wound. The animal was then returned to its cage, and allowed to 
regain consciousness. This typically occurred in ten to fifteen minutes. The 
animals were monitored very closely during the first two weeks. This initial 
monitoring was necessary to ensure the complete success of the surgeries as 
any noticeable problems would have been evident in the first two weeks.
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Potential problems include: loss of foot use, loss of leg use, infection, lethargy, 
and pain. Approximately 10 days post surgery, the staples were removed.
Sacrifice
The animals were sacrificed using carbon dioxide asphyxiation, according 
to fiie following schedule listed in Table 2. The dated sacrifice table can be 
found in Appendix D.
Table 2. Sacrifice schedule (number of animals).
Three month Six month Nine month
Operated control group 3 3 3
Experimental group 3 3 3
Unoperated control group 3 3 3
Harvest
Immediately after the animals were euthanized by carbon dioxide 
asphyxiation, soft tissue surrounding the femur was dissected. The femur was 
removed, placed into a 0.9% NaCI solution and frozen. The femurs remained 
frozen until testing.
Histological Sectioning
Undecalcified Sectioning
Undecalcified Materials. Technovit 7230 VLC (Exakt Corporation), 
Technovit 7210 VLC (Exakt Corporation), Technovit 7200 VLC resin (Exakt 
Corporation), Technovit 4000 (Exakt Corporation), small plastic slide 2”x3” (Exakt 
Corporation), large plastic slide 3”x4” (Exakt Corporation), 2-Hydroxyethyl- 
methacrylate 97% (Aldrich Corporation), Exakt standard cutting and grinding
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system, 10% Carson Millonig formalin solution (Statlab medical products), 
phosphate buffered saline 1X (HyClone), 70% ethyl alcohol (Aaper Alcohol and 
Chemical Company), Histolux HX (Exakt Corporation).
Undecalcified Embedding, Femurs were stored in 10% solution of neutral 
buffered formalin, for tissue preservation. The time each femur was allowed to 
remain in Formalin varied according to the euthanizing schedule of subsequent 
groups. Minimum time required was 48 hours but no sample remained for less 
than two weeks. After removal from formalin, the bones were washed in 
phosphate buffered saline, rinsed in distilled water and transferred to 70% 
ethanol refrigerated. The bones underwent an increasing gradient of 2- 
hydroxyethyl-methacrylate/nanopure water followed by several changes of 
Technovit 7200VLC resin. The resin embedding procedure is shown in Table 3.
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Table 3. Undecalcified histological embedding procedure.
100% Technovit 7200 - vacuum for 72 hours
wash in phosphate buffered saline
Histolux for 6 hours
100% Technovit 7200 - vacuum for 72 hours
oven at 60” C overnight
10% neutral buffered formalin
70% ethyl alcohol - 4°C for 72 hours
rinse in distilled water
100% Technovit 7200 - vacuum for 72 hours
96% 2-hydroxyethyl-methacrylate 
vacuum for 24 hours
100% 2-hydroxyethyl-methacrylate 
vacuum for 24 hours
70% 2-hydroxyethyl-methacrylate 
vacuum for 24 hours
50/50 2-hydroxyethyl-methacrylate and 
Technovit 7200 agitation for 24 hours
80% 2-hydroxyethyl-methacrylate 
vacuum for 24 hours
50% 2-hydroxyethyl-methacrylate 
vacuum for 24 hours
100% 2-hydroxyethyl-methacrylate 
vacuum for 24 hours
Samples placed into plastic dished filled 
with Technovit 7200 and held in place 
with a drop of Technovit 7230 VLC
Histolux exposes samples to two hours of 
fluorescent light and four hours of ultraviolet 
light at 450nm, causes polymerization 
of Technovit 7200
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Following embedding, samples were sandwiched between a large and 
small slide then sectioned using the specially designed diamond-tipped band 
saw, Figure 8, in the Exakt system. The sample was fixed to the large slide 
using Technovit 4000, which is a three part epoxy. After fixing the sample to the 
large slide, the resin block was ground down, using the grinder in Figure 9, until 
sample was in the surface plane of the block. A small slide was attached to the 
ground side of the block using Technovit 7210 VLC. After adherence of the 
sample to the small slide, the complex was attached to the Exakt saw. The blade 
was set to approximately 100pm and allowed to cut on a speed setting of two. 
This low setting caused slower cutting but less waste. After cutting, the slices 
were placed on the Exakt grinder, using increasing grits of sandpaper from 800 
to 4000, and they were constantly measured until the specimen thickness was 
between 10 and 20 micrometers.
Figure 8. Exakt cutter.
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Figure 9. Exakt grinder.
Undecalcified HistologicalStaining Materials. Hematoxylin crystals (Acros 
Organics), 95% ethyl alcohol (Aaper Alcohol and Chemical Company), ferric 
chloride 29% aqueous (Sigma Chemical Company), hydrochloric acid (Fisher 
Scientific Company), acid fuchin (Sigma Chemical Company), glacial acetic acid 
(Fisher Scientific Company), Xylidin-Ponceau (Chroma), Azophloxin (Chroma), 
Orange-G (Sigma Chemical Company), Molybdatophosphor acid (Sigma 
Chemical Company), Light Green (Sigma Chemical Company). Table 4 lists the 
undecalcified staining procedure.
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Table 4. Undecalcified histological staining procedure.
Light green 
15 minutes
Undecalcified section
Light microscopy
Orange-G 
5 minutes
Weigerts ferric 
hematoxlin 
15 minutes 1ml hydrochloric acid
880ml 0.2% glacial acetic acid
20ml of 0 5g Azophloxin and 0.2ml glacial acetic acid in 100ml diH 20
Masson solution 
(Goldner I)
7 minutes
100ml of 33ml of fuchsin and 1ml glacial acetic acid in 100ml diH 20  and 
66ml of 1g Xylidin-Ponceau and 1ml glacial acetic acid in 100 ml diH 20
equal parts of 1 % hematoxlin in 95% ethyl alcohol and 4ml of 
29% aqueous ferric chloride dissolved in 95ml diH 20
0.5g Light Green and 1ml glacial acetic acid in 500ml diH 20
10g Orange-G and 15g Molybdatophosphor acid in 500ml diH 20
Decalcified Histology Materials
10% Carson Millonig formalin solution (Statlab medical products), Cal-Ex 
(Fisher Diagnostics), 100% ethyl alcohol (Aaper Alcohol and Chemical 
Company), Formula 83 (CBG Biotech), TissuePrep 2 paraffin wax (Fisher 
Scientific), sodium chloride (Fisher Scientific), potassium chloride (Aldrich 
Chemical Company, Inc.), potassium phosphate (Sigma Chemical Company), 
sodium phosphate (Sigma Chemical Company), nanopure water.
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1X Phosphate Buffered Saline. 0.8g sodium chloride, 0.02g potassium 
chloride, 0.02g potassium phosphate, 0.11g sodium phosphate, 1L nanopure 
water, pH 7.2-7.4.
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Decalcified Histological Procedure. The decalcified histological embedding 
procedure is shown in Table 5:
Table 5. Decalcified histological embedding procedure.
95% ethyl alcohol (1 hour)
80% ethyl alcohol (1 hour)
Formula 83 (1 hour)
Formula 83 (1hour)
100% paraffin (overnight)
3 washes 1X phosphate buffered saline (1 hour each)
100% ethyl alcohol (1 hour)
embed and section
100% paraffin (1 hour)
10% neutral buffered formalin (38 hours)
70% ethyl alcohol (overnight)
100% paraffin (1 hour)
100% ethyl alcohol (1 hour)
Cal-ex (18 hours)
3 washes 1X phosphate buffered saline (30 minutes each)
The samples were placed into a glass jar on top of gauze. The gauze 
allowed the dissolved calcium to fall away from the bone, preventing interference 
with further decalcification.
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Following the final paraffin step, the samples were embedded into a 
paraffin block using Miles Tissue Tek II, Tissue Embedding Center 4603 (GMI, 
Inc.), Figure 10.
Figure 10. Miles Tissue Tek II.
The samples were cut into seven micrometer slices on an 820 Spencer 
microtome (American Optical Corporation).
Histological Analysis 
Stained histological sections, undecalcified and undecalcified, were 
photographed using an Olympus digital camera connected to an Olympus CX41 
light microscope at 4x magnification. Areas of bone were marked using Adobe 
Photoshop 7.0 edge finding option (areas not automatically selected were 
manually selected). Using the software, the number of pixels were found and 
compared to the overall number of pixels as well as to the number of pixels in 
other testing groups.
Post Harvest Analysis
Microcomouted Tomography
Microcomputed Tomography was preformed (courtesy of Animal 
Resources, Louisiana State University Health Sciences Center, Shreveport,
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Louisiana) on a MicroCAT II; model MCII-UAAI following standard operating 
procedure. Each femur, along with the contra-lateral side, was run for 512 scans 
along the defect site. This data was compiled into 2-D and 3-D images. 
Mechanical Testing
Four point bend test was performed on an Instron 4202 (Instron 
Corporation, Norwood, MA) in a customized apparatus (see Figure 11). The 
fulcrum points were 8mm apart and the head speed was 10mm/min. Load was 
applied using either a 100N load cell or 10kN load cell.
Attaches
to
Instron
4 mm
defect
Figure 11. Mechanical testing apparatus.
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CHAPTER 3
RESULTS 
Chitosan Characterization
Fourier Transform Infrared 
Spectroscopy
Fourier transform infrared spectroscopy (FTIR) passes a known 
wavelength of infrared light through a sample and records amount of energy 
absorbed by the molecule. Spectra for crawfish chitosan, chitosan glutamate 
and crawfish chitosan, chitosan monomer is shown in Figures 12 and 13.
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Figure 12. Crawfish chitosan and chitosan glutamate -  FTIR.
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Chitosan Monomer vs. Batch 005 (Run 1)
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Figure 13. Crawfish chitosan and chitosan monomer -  FTIR.
Chitosan glutamate, chitosan monomer and crawfish chitosan peak 
locations are located in Table 6. Peaks at 3628 cm'1, 2344 cm'1, 1654 cm'1 and 
1089 cm'1 were all shared between chitosan glutamate, chitosan monomer and 
crawfish chitosan. The peak located at 3628 cm'1 is associated with hydroxyl 
groups. The peak located at 2344 cm'1 is associated with solid phase amine 
groups. The peak at 1654 cm'1 is associated with deformation vibration of 
primary amine groups and the peak at 1089 cm'1 is associated with CH-OH 
bonding.
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Table 6. Common FTIR peak locations.
Common FTIR peak locations
Chitosan Monomer Chitosan Glutamate Crawfish Chitosan
3628.893 3627.928 3628.893
2344.052 2353.212 2344.052
1654.426 1654.426 1654.426
1089.834 1089.798 1089.672
1H Nuclear Magnetic Resonance 
Spectroscopy
1H nuclear magnetic resonance spectroscopy (NMR) aligns protons with 
intrinsic magnetic moments with a powerful external magnetic field and perturbs 
the alignment using an electromagnetic field. Perturbations are measured and 
recorded. All nuclei with odd numbers of protons and some with even number of 
protons have intrinsic magnetic moments; 1H and 13C are most widely used.
Similar peaks were located in all three 1H NMR spectra: crawfish chitosan, 
chitosan monomer, and chitosan glutamate. 1H NMR spectral analysis is in 
Figure 14. Peak locations were noted by distance from peak center to nearest 
quantitative part per million. Common peaks were: 0.235 inches to the right of 
one part per million, 0.149 inches to the right of two parts per million, 0.070 
inches to the right of three parte per million, and 0.050 inches to the left of four 
parts per million. The peaks located 0.235 inches to the right of one part per 
million and 0.070 inches to the right of three parte per million are associated with 
amine groups. The peak located at 0.149 inches to the right of two parts per 
million is associated with hydroxyl groups.
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Figure 14. Comparison of NMR spectra.
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Differential Scanning Calorimetry
In differential scanning calorimetry (DSC), differences in amount of heat 
required to increase the temperature of a sample and a reference are measured 
as a function of temperature. During melting, more heat is flowing to the sample, 
this is an endothermic reaction. During crystallization, less heat is required to 
raise the temperature (less heat is flowing to the sample), this is an exothermic 
reaction. DSC measures amount of energy absorbed or released compared to a 
control. In Figure 15, crawfish chitosan DSC results are shown for control (empty 
pan, left) and crawfish chitosan (right). In Figure 16, industrial chitosan DSC 
results are shown with control (empty pan, left) and industrial chitosan (right). 
Crawfish chitosan appears more amorphous than industrial chitosan due lack of 
peak and troughs in the DSC spectra of crawfish chitosan, compared to various 
endothermic and exothermic cycles from the industrial chitosan DSC spectra.
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Figure 16. Industrial chitosan -  DSC.
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Gross Anatomy
Six Month
From gross anatomical analysis, operated control samples grew deformed 
with the defect completely filled with fibrous tissue (Figure 17). Bone growth 
along the dorsal side of the plate was significantly increased compared to the 
three month operated control. In experimental samples, the defect was either 
partially healed with a slight defect present (Figure 18) or completely healed with 
slight visual evidence of small amounts of fibrous tissue (Figure 19).
Figure 17. Six mo. Rat 6 left operated control -  gross.
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Figure 18. Six mo. Rat 13 left experimental -  gross.
Figure 19. Six mo. Rat 14 left experimental -  gross.
Nine Month
From the gross anatomical analysis, operated control samples showed 
complete fibrous ingrowth (Figure 20). Upon removal of the plate, the defect was 
present and the bone had no structural support. Bone growth was observed 
along the dorsal side of the plate, increased from the six month operated control 
group. In the experimental group, the defect was completely healed with no 
evidence of fibrous tissue (Figure 21). No bone growth was visualized along the 
dorsal plane of the plate.
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d e f e c t  s i t e
Figure 20. Nine mo. Rat 19 left operated control -  gross.
Figure 21. Nine mo. Rat 18 left experimental -  gross.
Undecalcified Histological Sectioning 
In order to determine the presence of bone, a sample from each time 
frame and tested group underwent undecalcified sectioning and staining with 
Goldner’s’ Trichrome Method (muscle -  red, collagen (bone) -  green, cytoplasm 
(fibrous tissue) -  bright red, nucleus -  brownish black). All photographs were 
taken at 4x magnification with a light microscope, unless otherwise noted.
Six Month
At six month time interval, in the operated control group, fibrous tissue 
was present in the defect site (Figure 22). Bone was present juxtaposed to 
fibrous tissue. In the experimental group, the defect was filled with bone with
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
64
voids, indicated by white areas (Figure 23). Undisturbed bone from the six 
month group is in Figure 24.
Figure 22. Six mo. operated control (Goldner’s, undecal., 5L-WW).
Figure 23. Six mo. experimental (Goldner’s, undecal., 13L-SS).
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Figure 24. Six mo. unoperated control (Goldner’s, undecal., 25L-MM).
Nine Month
At nine month time interval, in the operated control group, fibrous tissue 
was present in the defect site (Figures 25, 26, 27 & 28). The amount of fibrous 
tissue increased from the six month group. Delineation between fibrous tissue 
and bone improved and the fibrous tissue appears denser. In the experimental 
group, the defect was almost entirely repaired. Repair occurred in the medial to 
lateral direction as observed in Figure 29 and 30 (Figure 29 was sectioned prior 
to Figure 30). Bone was organized and the intermedullary canal was well 
defined (Figure 30). Undisturbed bone from the unoperated control group is in 
Figure 31.
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Figure 25. Nine mo. operated control (Goldner’s, undecal., 7R-69).
Figure 26. Nine mo. operated control (Goldner’s, undecal., 7R-69).
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Figure 27. Nine mo. operated control (Goldner’s, undecal., 7R-76).
Figure 28. Nine mo. operated control (Goldner’s, undecal., 7R-81).
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Figure 29. Nine mo. experimental (Goldner’s, undecal., 17L-62).
Figure 30. Nine mo. experimental (Goldner’s, undecal., 17L-64).
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Figure 31. Nine mo. unoperated control (Goldner’s, undecal., 27R-59).
Histological Quantitative Data 
From bone pixilation, the percentage of bone in each group can be 
compared (Figure 32). In each time interval, more bone was present in the 
experimental group compared to the operated control group. At the six month 
time interval, 35.58% bone growth was calculated in the experimental group and 
30.09% bone growth was recorded in the operated control group. As expected, 
nine month time interval demonstrated the highest percentage of bone growth in 
both groups. The experimental group experienced 42.82% bone growth while 
the operated control group experienced 40.16%.
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Figure 32. Histological data - percent bone growth.
Decalcified Histological Sectioning 
Multiple slices were cut from each sample and stained with either 
Hematoxylin and Eosin or Safranin O. Hematoxylin is a basophilic dye, it binds 
to basic tissue components whereas Eosin is an acidophilic dye, and it binds to 
acidic tissue components. With H&E staining, nuclei stain blue to blue/black, 
collagen and skeletal muscle stain bright red, smooth muscle stain pink/red and 
red blood cells and fibrin stain bright red/orange. All photographs were taken 
with a light microscope at 4x magnification. The purpose of H&E staining was to 
provide a simple secondary method for determining the presence of bone. The 
purpose of Safranin O staining was to determine if residual cartilage remained in 
presence of the crawfish chitosan bone graft. Across all three groups (operated 
control, experimental and unoperated control) and time intervals, H&E staining 
was consistent with bone. None of the groups (operated control, experimental 
and unoperated control) at any time interval stained positive with Safranin O for
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cartilage. Hematoxylin and Eosin stained three month slides are in Figures 33, 
34 and 35, Safranin O stained specimens are in Figures 36, 37 and 38. 
Hematoxylin and Eosin stained six month slides are in Figures 39 and 40, 
Safranin O stained specimens are in Figures 41 and 42. Hematoxylin and Eosin 
stained nine month slides are in Figures 43, 44 and 45, Safranin O stained 
specimens are in Figures 46,47 and 48.
Figure 33. Three mo. operated control (H&E, decal., 8L-1).
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Figure 34. Three mo. experimental (H&E, decal., 11L-1).
Figure 35. Three mo. unoperated control (H&E, decal., 3L-1).
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Figure 36. Three mo. operated control (Safranin O, decal., 1L-2).
Figure 37. Three mo. experimental (Safranin O, decal., 10R-3).
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Figure 38. Three mo. unoperated control (Safranin O, decal., 3L-2).
m  <
Figure 39. Six mo. operated control (H&E, decal., 6L-1)
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Figure 40. Six mo. experimental (H&E, decal., 14L-2).
Figure 41. Six mo. operated control (Safranin O, decal., 4R-2).
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Figure 42. Six mo. experimental (Safranin O, decal., 14L-1).
Figure 43. Nine mo. operated control (H&E, decal., 20L-1).
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Figure 44. Nine mo. experimental (H&E, decal., 18L-2).
Figure 45. Nine mo. unoperated control (H&E, decal., 20R-2)
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Figure 46. Nine mo. operated control (Safranin O, decal., 20L-3).
Figure 47. Nine mo. experimental (Safranin O, decal., 18L-3).
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Figure 48. Nine mo. unoperated control (Safranin O, decal., 29L-2).
Post Harvest Analysis
Microcomputed Tomography
Microcomputed tomography was preformed on a MicroCAT II; model 
MCII-UAAI following standard operating procedure. Each femur, along with the 
contra-lateral side, was run for 512 scans along defect site. This data was 
compiled into 2-D and 3-D images.
Six Month. In the six month operated control group, defect was still visible 
(Figure 49 & 50) and bone underwent deformed repair (Figure 49). In Figure 50, 
denser cortical bone is lining the defect, thereby preventing formation of the 
intermedullary canal and halting further repair processes. In the experimental six 
month group, repair is significantly improved compared to the operated control 
group during the same time interval. The intermedullary canal is continuous 
throughout the femur. Defect site has a slight defect in cortical bone on ventral
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surface. Figures 51 and 52 show defects which slightly impede the 
intermedullary canal. In the three dimensional rendering (Figure 53), the dorsal 
plane of the defect is completely healed and undistinguishable from surrounding 
bone. Figure 54 demonstrates an undefected femur at this time interval.
Figure 49. Six mo. Rat 6 operated control (single slice) - pCT.
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Figure 50. Six mo. Rat 6 operated control (single slice) - pCT.
Figure 51. Six mo. Rat 14 experimental (single slice) - pCT.
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Figure 52. Six mo. Rat 14 experimental (single slice) - pCT.
Figure 53. Six mo. Rat 14 experimental (3-D) - pCT.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
83
Figure 54. Six mo. Rat 24 unoperated control (single slice) - pCT.
Nine Month. In the nine month operated control group, cortical bone 
defined edges of the defect (Figure 55) and prevented complete repair of the 
intermedullary canal. In Figures 55, 56 and 57, lack of repair is visually 
definable. In the nine month experimental group, repair is essentially complete 
with only small amounts of defects present. The intermedullary canal is virtually 
complete (Figure 58) and three dimensional rendering shows lack of a visually 
apparent defect (Figure 59) and presence of a complete intermedullary canal 
(Figure 60). Figures 61 and 62 show unaltered nine month femurs.
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Figure 55. Nine mo. Rat 19 operated control (singel slice) - pCT.
Figure 56. Nine mo. Rat 19 operated control (3-D) - pCT.
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Figure 57. Nine mo. Rat 19 operated control (3-D) - pCT.
Figure 58. Nine mo. Rat 18 experimental (single slice) - pCT.
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Figure 59. Nine mo. Rat 18 experimental (3-D) - pCT.
Figure 60. Nine mo. Rat 18 experimental (3-D) - pCT.
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Figure 61. Nine mo. Rat 28 unoperated control (3-D) - pCT.
Figure 62. Nine mo. Rat 28 unoperated control (single slice) - pCT.
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Mechanical Testing
Mechanical testing was performed to compare stiffnesses and fracture 
loads between the groups and time intervals. Due to the small nature of the 
samples, a custom four point bending apparatus was designed to distribute load 
over the sample length (Figure 11). The results are compiled in Figure 67 and 
Table 7.
Six Month. Figures 63, 64 and 65 illustrate bending moment versus 
displacement for the six month group. All four point bending tests were carried 
out to failure. Sample size and load data was used to calculate bending moment.
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Figure 63. Six mo. Rat 04 right operated control - 4-point bending.
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Figure 64. Six mo. Rat 14 left experimental - 4-point bending.
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Figure 65. Six mo. Rat 15 left experimental - 4-point bending.
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Nine Month. Figure 66 illustrates bending moment versus displacement for 
the nine month group. All four point bending tests were carried out to failure. 
Sample size and load data was used to calculate bending moment.
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Figure 66. Nine mo. Rat 16 left experimental - 4-point bending.
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Mechanical Data
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Figure 67. Mechanical data - bending moments at failure.
Table 7. Stiffness, bending moment and displacement.
Sample
ID Month Description
Stiffness
((N*mm)/mm)
Bending
moment
(N*mm)
Displacement
(mm)
Rat 4 Six Operated control group 1662.400 641.132 0.429
Rat 14 Six Experimentalgroup 1327.900 570.332 0.461
Rat 15 Six Experimentalgroup 802.810 357.388 0.426
Rat 16 Nine Experimentalgroup 222.160 227.372 1.032
Rat 19 Nine Operatedcontrol defect filled with fibrous growth
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CHAPTER 4
DISCUSSION
Characterization
The purpose of crawfish chitosan characterization is to create a 
“fingerprint”, a series of test results that describe the chemical and physical 
composition of the compound. The importance of chemical fingerprinting is to 
identify crawfish chitosan from patented procedure [104] from other types of 
chitosan. In order to distinguish crawfish chitosan from non-chitosan product, 
“fingerprinting” tests are run on known chitosan samples in parallel with crawfish 
chitosan and similarities are noted. Determining exact functional groups 
associated with peak location is beyond the scope of this project. Noting 
similarities between crawfish chitosan (extracted using patented procedure [104]) 
and a control not only defines crawfish chitosan’s individuality, it also determines 
whether or not chitosan is present.
Fourier Transform Infrared Spectroscopy
Fourier transform infrared spectroscopy (FTIR) passes a known 
wavelength of infrared light through a sample and records the amount of energy 
absorbed by the molecule. In this experiment, crawfish chitosan, chitosan 
monomer and industrial chitosan were run on Fourier transform infrared
92
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spectroscopy to determine the presence of similar chemical groups. Similar 
peaks were found at 3628 cm'1, 2344 cm'1, 1654 cm'1 and 1089 cm'1. From this 
data, die presence of similar chemical groups can be ascertained. The peak 
located at 3628 cm'1 is associated with hydroxyl groups. The peak located at 
2344 cm'1 is associated with solid phase amine groups. The peak at 1654 cm'1 
is associated with the deformation vibration of primary amine groups and the 
peak at 1089 cm'1 is associated with CH-OH bonding.
Nuclear Magnetic Resonance Spectroscopy
Nuclear magnetic resonance spectroscopy (NMR) aligns protons with 
intrinsic magnetic moments with a powerful external magnetic field and perturbs 
the alignment using an electromagnetic field. The perturbations are measured 
and recorded. Each chemical group perturbs differently depending on 
composition (i.e. chemicals involved and bond types). From similar perturbations 
(peak locations) we can ascertain the presence of similar chemical groups.
To determine exact location of a peak, the corresponding peak centerpoint 
location was found on the x-axis. This distance was measured to the nearest 
whole number. Comparison of chitosan glutamate, crawfish chitosan and 
chitosan monomer, through NMR analysis, displayed the presence of three 
similar peaks (i.e. three similar chemical groups). The peak at zero is a control 
used to determine the location of zero parts per million, and the peak around four 
is deuterated (heavy) water (water containing deuterium atoms instead of 
hydrogen, deuterium is twice as heavy as hydrogen because it contains an 
additional neutron). Similar peaks were found 0.235 inches to the right of one
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part per million, 0.149 inches to the right of two parts per million, 0.070 inches to 
the right of three parts per million, and 0.050 inches to the left of four parts per 
million (Figure 13). The common peak locations define the presence of chemical 
groups similar among the three different types of chitosan tested (crawfish 
chitosan, chitosan glutamate and chitosan monomer). The peaks located 0.235 
inches to the right of one part per million and 0.070 inches to the right of three 
parts per million are associated with amine groups. The peak located at 0.149 
inches to the right of two parte per million is associated with hydroxyl groups. 
Differential Scanning Calorimetry
In differential scanning calorimetry (DSC), differences in amount of heat 
required to increase the temperature of a sample and a reference are measured 
as a function of temperature. During melting, more heat is flowing to the sample, 
this is an endothermic reaction. During crystallization, less heat is required to 
raise the temperature (less heat is flowing to the sample), this is an exothermic 
reaction. DSC measures the amount of energy absorbed or released. Lack of 
well defined peaks (crystallization) or troughs (melting) defines an amorphous 
polymer. Amorphous biopolymers degrade quicker than crystalline polymers and 
more completely, in addition the structure is more uniform and properties are 
more predictable.
Differential scanning calorimetry was performed on crawfish chitosan and 
a control (empty pan) to determine lack of crystalline form (for comparison, 
industrial chitosan was also run). Results demonstrated that crawfish chitosan 
appears amorphous due to the lack of peaks and troughs in the crawfish chitosan
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DSC spectra, compared to industrial chitosan which undergoes several cycles of 
melting and crystallization.
Experimental Design 
Experimental design consisted of an experimental group, an operated 
control group and an unoperated control group. The experimental group 
consisted of animals with a plated femur, critical sized defect and crawfish 
chitosan bone graft paste. The operated control group consisted of animals with 
a plated femur and a critical sized defect (no crawfish chitosan bone graft paste). 
The unoperated control group contained animals that did not undergo any 
surgical procedure. An unoperated control group was necessary, as opposed to 
obtaining undefected bone data from contra-lateral femurs, because surgical 
conditions dispose the animal to preferential leg treatment thereby tainting the 
unoperated control results. In addition to the groups listed above, a sham group 
should have been included. A sham group (plated bone with no critical defect) 
would have provided data regarding Hie effect of the plate on the femur and 
animal bias, due to surgery the animal will preferentially use their contra-lateral 
leg.
Each group consisted of three animals across three time periods. The 
number of animals in each group is described in the table two. Following the 
current study, surgeries were performed on an additional ten animals as part of 
an ongoing study (Appendix E) in an attempt to increase sample size and obtain 
more sophisticated test results. These additional femurs were harvested 
following a three month repair period and sent to the Materials Science
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
96
Department at Massachusetts Institute of Technology (MIT) for nano-indentation 
testing and backscatter electron microscopy.
Discrepancies in mechanical data are probably due to small sample size. 
Most of the mechanical data was based off of one sample thereby negating the 
ability to perform statistical analysis. The number of animals used was dictated 
by lack of funding for this project. With adequate funding, sample size can be 
increased and statistical analysis could be preformed thereby possibly providing 
more accurate results. This was a preliminary study to determine the efficacy of 
crawfish chitosan as a cell delivery vehicle. The small sample size could have 
possibly provided inaccurate results regarding bone growth. As a preliminary 
study, the results provided are sufficient to instigate additional studies to find out 
the exact role of crawfish chitosan in bone defect repair.
Gross Anatomy
In the six month group, profound visualizations can be made due to 
deformities present in the operated control femur. Operated control femurs 
appeared to have a high amount of fibrous tissue along with a deformed anatomy 
(Figure 68). Fibrous tissue caused bone discoloration.
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Figure 68. Deformed femur, six month operated control group (5L).
Experimental femurs, six month group, displayed appropriate morphology 
with presence of a slight defect along the ventral femoral surface. Upon plate 
removal, experimental femurs displayed rigidity and structural soundness 
compared to operated control femurs which displayed flexibility at the defect site. 
In the nine month group, experimental femurs visually demonstrated complete 
repair with no signs of defects present. Operated control femurs exhibited 
fibrous growth throughout the defect site. Upon plate removal, experimental 
femurs showed complete repair and inflexibility whereas operated control femurs 
demonstrated severe flexibility and lack of structural soundness. All plated 
femurs demonstrated flatted morphology, at plate location, due to plate presence. 
On some femurs bone began to slightly encompass the plate on the proximal 
portion. Since mechanostimulation promotes bone growth, change in load 
distribution due to the plate, along with angle at which a rat’s leg naturally splays 
is a probable cause (Figure 69).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
98
Figure 69. Lewis rat skeleton.
After surgery, rats gain weight due to lack of significant movement and 
therefore have less space for movement. This lack of significant movement 
reduces mechanostimulation on all loaded skeletal structures. Since repair 
processes strive under loaded conditions and these lethargic animals presented 
reduced loaded conditions, bone growth decreased from the three month group 
to the nine month group. Mechanostimulation is an important part of bone 
growth and repair. During all time intervals, animals were confined to cages 
10.5" W x 19" L x 8" H (Allentown Caging Equipment, Inc., Allentown, N.J.) 
(Figure 70), physical activity was negligible and feed intake was constant (free 
choice). Reduced physical activity led to decreased mechanostimulation which 
led to weakened repaired bone [166,167].
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Figure 70. Rat housing.
Undecalcified Histological Sectioning 
During each time interval (three, six and nine months) repair occurred 
faster in experimental groups compared to operated control groups. Repair, in 
the experimental group, lacked fibrous tissue and, histologically, appeared to 
consist primarily of cortical bone. In comparison, operated control samples 
demonstrated repair with a relative high concentration of voids and fibrous tissue. 
Defects were present, in operated control femurs, after nine months of repair 
time.
Slide color variation is due to specimen thickness, whereby more tissue is 
stained. General colors are the same with slight shade variation. Exact 
duplication in slide thickness was attempted but not always achieved. The 
process of grinding resin embedded specimens to exact thickness consisted of 
periodically removing the slide from the grinder and measuring thickness with a 
micrometer and either replacing the slide onto the grinder or removing it for 
staining.
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Histological analysis demonstrated presence of bone. Mechanical 
analysis demonstrated decreased strength probably due to decreased 
mechanostimulation. Jarvinen et al. [166] and Umeruma et al. [167] described 
minimodeling caused by mechanostimulation. Minimodeling is growth/repair 
initiated by mechanostimulation which influences alignment and thickness of 
trabeculae. Minimodeling does not affect external bone dimensions.
Six Month
Six month undecalcified histological operated control sections displayed 
significant fibrous growth at defect site. Tissue juxtaposed to defect site was 
highly infiltrated with fibrous tissue (Figure 22). Analysis of later sections 
revealed fibrous tissue decreased to area in defect site. Six month experimental 
histological sections displayed superior growth compared to the operated control 
samples. Repaired bone tissue displayed continuous growth although large 
voids, white spaces, were noticed (Figure 23).
Six month experimental histological sections showed improved repair 
compared to operated control samples. While voids were present in 
experimental samples, operated control samples had complete defects present. 
Nine Month
Nine month undecalcified operated control sections displayed a high 
relative percentage of fibrous tissue in the defect site. Unlike the six month 
group, fibrous tissue was juxtaposed to cortical bone. In nine month 
undecaicified experimental sections, defects were only slightly present with no
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signs of fibrous tissue or voids. Ail defects, in experimental femurs, were 
repaired with, histologically, cortical bone.
Nine month experimental group demonstrated a relative higher 
percentage of bone compared to operated control femurs from the same time 
period.
Decalcified Histolooical Sectioning 
Bone repair occurs by endochondral ossification, whereby mesenchymal 
cells differentiate into chondrocytes which form scaffolding for osteoblasts and 
mineral deposition. Chitosan is described in several published papers [1, 61,62, 
70, 83] as a successful biomaterial in cartilage tissue engineering. Specimens 
were stained with Safranin O staining to determine presence of residual cartilage 
remaining from the crawfish chitosan bone graft repair process. Both groups 
(operated control and experimental) tested negative for the presence of residual 
cartilage which implies that the crawfish chitosan bone graft does not cause 
residual cartilage formation, although results may have been different if samples 
were observed at shorter time intervals.
Hematoxylin and Eosin (H&E) is a general stain. For this experiment, 
H&E was used as a secondary detector of bone; undecalcified Goidner’s’ 
Trichrome sections were primary. After comparing stained slides, H&E and 
Goidner’s’ Trichrome, from the operated control and experimental groups to 
slides from the unoperated control groups, presence of bone was verified. All 
experimental samples displayed bone at defect sites, in varying degrees, while
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operated control samples displayed fibrous tissue, histologically, during all time 
intervals.
Post Harvest Analysis
Four-Point Bending
In Table 7, values of bending moments at failure are listed. Values are 
higher at six months and lower at nine months. This trend is opposite what we 
would expect. According to Umemura et al. [167] and JSrvinen et al. [166] 
loading results increase bone strength but not bone size. According to Jarvinen 
et al. [166] loading (exercise) for 20 minutes a day / five days a week for nine 
weeks causes mini-modeling in bone, which is a change in the alignment of 
trabeculae without changing bone dimensions or adding bone minerals. Loading 
created more dense trabeculae, thereby creating stronger bones. The 
decreased bending moment for failure at nine months is probably a consequence 
of lack of loading caused by a confining environment and a constant food 
supply which led to a lethargic lifestyle. Another possible explanation for the 
decrease is natural aging. The average lifespan of a male Lewis rat is 
approximately two years. The animals were two months old pre-surgery and, in 
the case of the longest group, kept until they were approximately 11 months old. 
Bones heal more rapidly in juveniles compared to adults. At the inception of this 
project, tine animals were juveniles and at the conclusion of the study they were 
mature adults.
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Microcomputed Tomography
Microcomputed tomography (pCT) is a series of x-ray images compiled 
together into a three dimensional image. Individual slices are available for 
viewing as well as three dimensional images. Microcomputed tomography 
images of the bone graft site displayed progressive repair in experimental 
samples compared to operated control femurs, which displayed a complete 
defect throughout all time periods. Operated control femurs, across all time 
intervals, displayed similar characteristics. All operated control samples had 
incomplete intermedullary canals, defect presence (appropriate for a critical sized 
defect) and dense tissue growth over bone ends at defect site. Likewise, 
experimental samples displayed similar characteristics across all time intervals. 
All experimental samples had a slight surface defect present (although size 
decreased as time progressed) and intermedullary canal was continuous 
throughout entire femoral length. Microcomputed tomography provided a non­
destructive technique to view internal composition without compromising sample 
integrity. Non-destructive microcomputed tomography testing allowed femurs to 
undergo additional testing, thus maximizing the quantity of data per sample.
Conclusion
The objective of this study was to extract, characterize and evaluate 
chitosan made from crawfish shells [104] in a critical size defect model [4,141] in 
rate as a synthetic bone graft material. The composite of this purified chitosan 
and calcium sulfate, in a paste form, was successfully used as a delivery system
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for osteoblasts and the results confirmed our hypothesis that such a system 
promotes bone growth.
The specific conclusions were:
1. The physical characterization by Fourier transform infrared spectroscopy 
(FTIR) of purified crawfish chitosan showed similar characteristics to that 
of a commercially pure and medical grade chitosan glutamate.
2. Differential scanning calorimetry (DSC) confirmed the amorphous nature 
of chitosan made from crawfish shells using Dr. Debi Mukherjee’s 
patented procedure.
3. Chemical characterization by nuclear magnetic resonance spectroscopy 
(NMR), when benchmarked against chitosan glutamate and chitosan 
monomer, showed remarkable similarity.
4. The animal evaluations of the composite paste for three, six & nine 
months examined by histology (undecalcified and decalcified), and 
microCT (pCT) demonstrated a high degree of bone ingrowth for the 
experimental group as compared to samples in the operated control group 
(defected and repaired without paste).
5. The use of pCT as a non-destructive tool to follow bone ingrowth was 
found to be very valuable. Although we used this technique mainly for 
qualitative purpose the data can be digitized to make more quantitative 
predictions.
6. Four point bending data at six months was somewhat anomalous, which 
may be due to small sample size and loss of strength due to lack of
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activity as the rats gained weight, in the nine month group, experimentai 
bending stiffness and failure load was higher compared to operated 
control samples, defects in the operated control femurs were filled with 
fibrous tissue and therefore could not be tested.
In this study, chitosan was extracted from crawfish shells, combined with 
plaster of Paris and cultured osteoblasts and used as a synthetic bone graft in a 
critical sized defect model. In addition to the novel method used for chitosan 
extraction from crawfish shells, this research demonstrates chitosan’s successful 
use as a cell delivery system.
Future Work
This preliminary study has great potential provided proper follow-up 
experiments are preformed. One possible experiment is comparing crawfish 
chitosan bone graft against a bone graft containing all components, except 
crawfish chitosan (i.e. the graft would contain plaster of Paris and osteoblasts). 
This would give a better description of the exact role of crawfish chitosan. In 
addition, more animals should be included to decrease biological variability and 
provide a basis for statistical analysis. A sham group (plate is attached to the 
femur but no defect is made) should be included. A sham group removes 
biological variability due to the plate by recording effects of the plate on the femur 
as well as effects of animal bias on the femur, as the animal will preferentially 
use the contra-lateral leg over the operated one. This data can be compared to 
the experimental groups to better define the role of crawfish chitosan. In Table 8 
is an experimental design for a future study, based on identical analysis to the
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current study being performed. In defected bone, repair should be complete 
within six months (unless a non-union has occurred); based on this the proposed 
study should only be carried out for six months. Since the purpose of this study 
is development of a bone graft that is osteoconductive, osteoinductive and 
osteogenic in a critical defect, the final graft repair is most important. Each 
group, excluding the unoperated control group, consists of 30 male Lewis rate. 
This provides 10 animals for each of the three destructive testing methods 
currently being used, decalcified histology sections, undecalcified histology 
sections and mechanical testing (all samples should undergo microcomputed 
tomography). The unoperated control group consists of 18 animals, six of each 
of the testing methods. The unoperated control animals will provide baseline 
date, therefore fewer animals are needed. Six animals in each testing group are 
enough to perform statistical analysis.
Prior to graft implantation, but post graft creation, osteoblast viability 
should be determined. This can be accomplished by a live-dead count on a 
hemocytometer. A count would provide the actual number of viable cells being 
used in the graft as well as reconfirm the non-toxicity of graft components. 
Osteoblasts are the components that are hypothesized to play an integral role in 
providing the crawfish chitosan bone graft with osteogenic properties. In order 
for the results to be as accurate as possible, osteoblast viability should be noted 
so any differences can be taken into account. This data would be useful as a 
possible source of discrepancies among post harvest results.
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The characterization of crawfish chitosan is important because it defines a 
“fingerprint” that signifies the presence of crawfish chitosan. Further analysis 
should be preformed to clearly define the location of specific molecular groups 
associated with specific peaks. To aid in fingerprinting, crawfish chitin should be 
tested along with crawfish chitosan. This will aid characterization by 
demonstrating the removal of acetyl groups as well as reconfirming the 
relationship between crawfish chitin and crawfish chitosan (i.e. does 
deacetylation do more than remove an acetyl group?).
In the current study, it is recommended to generate better mechanical 
data by using a more sophisticated technique and increase the number of 
animals. With this in mind an additional six rats with necessary controls were 
studied for three months. The animals were sacrificed and femurs were sent to 
the Biomaterials Laboratory at Massachusetts Institute of Technology (MIT) for 
nanoindentation testing and backscatter electron microscopy. The details are 
shown in the Appendix E. Table eight describes a possible future study.
Table 8. Experimental design for a future study.
Number of animals
Unoperated
control
group
Operated
control
group
Sham
group
Experimental 
group 1
Experimental 
group 2
Group
specifics No surgery
Critical 
defect 
and 
crawfish 
chitosan 
bone graft 
paste
Plated
femur
Critical defect 
with plaster of 
Paris and 
osteoblasts
Critical defect 
and crawfish 
chitosan bone 
graft paste
6 month 18 30 30 30 30
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APPENDIX A 
NUCLEAR MAGNETIC RESONANCE 
SPECTROSCOPY 
PROTOCOL
The nuclear magnetic resonance spectroscopy (NMRS) protocol includes 
a four hour incubation. To maximize time and ensure test completion in a timely 
fashion, deuterium chloride (DCI) and sodium deuteroxide (NaOD) were 
prepared 24 hours before test run. 1H NMRS aligns 1H molecules with an 
electromagnet and measures the amount of energy released when the molecule 
returns to its natural state. In order to prevent false readings, any reagents used 
in 1H NMRS preparation that contain hydrogen are replaced with a deuterated 
version. The deuterated version is molecularly heavier as it contains an 
additional neutron and is recorded on the spectra in a different location.
The nuclear magnetic resonance spectroscopy protocol is listed below:
The day prior to testing a 20% DCI solution is prepared in a 0.1 M solution 
and a 1M solution along with a 0.1M and 1M solution of NaOD, the diluent is 
deuterated water.
On the day of testing 33mg of crawfish chitosan was added to 3.3ml of 
D20. After two to three minutes, 250pl of 1M DCI is added to the crawfish 
chitosan mixture. After two to three minutes, 100pl of freshly made NaN02 is 
added. This mixture is allowed to sit in the dark for four hours at room 
temperature. During this incubation, 0.15M of the control, sodium 3- 
trimethylsilylpropionate-2,2’,3,3’-d4 (TMSP) is prepared. Following the incubation
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period, the sample is pH of the sample is checked and adjusted to between 3.8 
and 4.2 using DCI and NaOD. Once the pH was adjusted, the solution was 
centrifuged to remove any large particulate matter. Following centrifugation, 
700pl of the supernatant was placed into an NMR sample tube and 5pl TMSP 
was added. The tubes were inverted to mix and run on the NMRS using the 
following specifications:
Temperature: 90°C 
Sample spinning: 20Hz 
Number of scans: 64 
Proton spectral width: 10ppm 
Relaxation delay: 5s 
Pulse angle: 90°
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APPENDIX B
CELL CULTURE PROTOCOL
1. Stromal osteoblastic cells were obtained from the bone marrow of male 
Lewis rats, approximately six months old and 200-250 grams.
2. Following euthanasia by carbon dioxide asphyxiation, femora were 
aseptically excised, cleaned of soft tissue, washed in Dulbecco’s 
Modified Eagle’s Medium (DMEM), Penicillin G Streptomycin 
(antibiotic) and Amphotericin B (antimycotic). Concentration of the 
antibiotic-antimycotic solution is ten times the normal amount that is 
used in the media for growing cells.
3. The metaphyseal ends were cut off and the bone marrow was flushed 
from the midshaft with five milliliters of media (DMEM + 10% fetal 
bovine serum (FBS) + antibiotic-antimycotic solution) using a sterile 
syringe and collected in a sterile test tube.
4. Cell clumps were broken by repeatedly pipetting the ceil suspension.
5. The cell suspension was centrifuged at 1200 rpm for 10 minutes.
6. The cell pellet was resuspended in media (DMEM + 10% FBS + 
antibiotic-antimycotic solution + 10% Interleukin three) and seeded in a 
flask.
7. The following day, the media was removed and the cells were washed 
with a 10x concentration of antibiotic-antimycotic solution in phosphate 
buffered saline (PBS). New media (DMEM + 10% FBS + antibiotic-
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antimycotic solution + 10% Interleukin three) was put back into the 
flask.
8. The media was exchanged every two to three days until confluent then 
trypsinized.
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APPENDIX C
GRAFT COMPONENTS
Animal Month Calcium Sulfate
(g)
Crawfish Chitosan
(g)
Osteoblast 
Concentration 
(cells per ml)
10 3 0.5059 0.1250 2.60x10*
11 3 0.5048 0.1249 1.98x10*
12 3 0.5048 0.1249 2.28 x 10*
13 6 0.5022 0.1244 2.78x10*
14 6 0.5050 0.1234 2.65x10*
15 6 0.5656 0.1243 2.05x10*
16 9 0.5004 0.1246 1.98x10*
17 9 0.5017 0.1240 2.40x10*
18 9 0.5030 0.1247 1.90x10*
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APPENDIX D
SACRIFICE TIME TABLE
Surgery Date 6 months 9 months
O
pe
ra
te
d 
Co
nt
ro
l 
G
ro
up
Rat 4 4/20/2005 10/20/2005
Rat 5 4/21/2005 10/20/2005
Rat6 4/21/2005 10/20/2005
Rat 7 4/22/2005 1/27/2006
Rat 9 4/27/2005 2/8/2006
Rat 19 5/5/2005 2/8/2006
Rat 20 5/5/2005 2/8/2006
Ex
pe
rim
en
ta
l
G
ro
up
Rat 13 4/28/2005 10/27/2005
Rat 14 4/28/2005 10/27/2005
Rat 15 4/28/2005 10/27/2005
Rat 16 4/29/2005 2/1/2006
Rat 17 4/29/2005 2/1/2006
Rat 18 4/29/2005 2/1/2006
Un
op
er
at
ed
Co
nt
ro
l
G
ro
up
Rat 24 10/30/2005
Rat 25 10/30/2005
Rat 26 10/30/2005
Rat 27 2/7/2006
Rat 28 277/2006
Rat 29 2/7/2006
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APPENDIX E
ADDITIONAL ANIMAL SAMPLES
Following completion of the primary study, ten addition animals underwent 
surgery. Five of the additional animals were in an experimental group and the 
remaining were in an operated control group. Surgical methods were the same 
with animals in the experimental group receiving the crawfish chitosan paste and 
the operated control animals received no paste.
The purpose of the additional animals is to better characterize the graft 
with additional samples. The additional samples underwent microcomputer 
tomography (courtesy of Louisiana State University Health Sciences Center, 
Animal Resources, Shreveport, Louisiana) and were sent to the Biomaterials 
Laboratory at Massachusetts Institute of Technology for Backscatter Electron 
Microscopy and Nanoindentation. Results are pending.
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Section H. OVERVIEW AND RATIONALE OF STUDY:
The following information is Fequired to assist the committee with evaluating the appropriateness of the animal model and 
procedures to be used. All questions must be answered. Use additional pages if necessary. Abstracts from grant application 
forms are not acceptable. Be concise and respond in lay terms.
A. State the objective(s) of this protocol, significance, scientific merit, and what population this research will affect 
The objectives are:
1.To follow the lime course 3,6 & 9 months of healing of the rat femoral segmental bone defect filled with chitosan and 
Plaster of Paris composite paste and osteoblasts. The protocol of this fracture model was developed based on a 3-month 
pilot study (Protocol No. S-02-00) that was completed early this year. This paste is intended to be used as a synthetic 
bone graft substitute to repair bone defects in osteoarthrytic patients.
2. To apply the new technique of microcomputer tomography (pCT) to identify the development of bone in the segmental 
defect in the rat femur. This is a promising technique to quantify the changes in bone density and porosity. The Research 
Core Facility of LSUHSC is in the process of acquiring this instrument and it will be available to us on a fee basis in the 
nearfutune..................................................
3. To generate the safety and efficacy data of our chitosan paste for future Investigational Device Exemption (IDE) filing to 
Food and Drug Administration (FDA) which is needed before starting human clinical trials. This data will also increase the 
potential chances of licensing our chitosan patent (US 6,310, 188B1) to interested companies.
This research study is aimed towards the delivery of osteoblasts to treat osteoarthritis. Currently the annual US sales of 
bone graft substitute are $50 million and growing substantially (JBJS, 2001 Supplement 2, 98-103). This study is pivotal 
to complete the FDA regulatory needs and product licensing for commercialization.
B. Give the rationale for using animals In this project, the justification of the animal model chosen, and a justification for 
the number of animate requested. (Be Specific)
The animal model was chosen based on the following papers:
1. Einhorn TA, Lane JM, Burstein AH, Kopman CB, and Vigorita VJ. * The healing of segmental defects induced by 
demineralized bone matrix". J. of Bone and Joint Surgery, 1984, 66-A, 274-279.
2. Wolff DW, Goldberg VM, and Stevenson S ." Histomorphometric analysis of the repair of a segmental diaphyseal 
defect with ceramic and titanium fiber metal implants: effects of bone marrow”. J. Of Orthopaedic Research, 1994,12 
(3) 439-446.
There is no computer model to simulate the bone growth hence it needs animal experiments.
We will create a unilateral segmental defect of about 3 mm in a rat femur and fix the defect with a 4-hole titanium plate and 
four 2-mm screws following the protocol that we developed in our pilot study (S-02-00). In the first group the defects, in the 
rat femur will be fixed with a plate and screws and filled with chitosan paste. In the second group, the defect will be fixed with 
a plate and screws only without the paste. The third group would be the sham-operated control. We must have a minimum 
of 6 rats per group for analysis of statistical significance. For our time periods of 3, 6 & 9 months we would need 54 rats 
(3x6x3 =54). Additionally, we would also need a minimum of 6 rats to collect the bone marrow needed to expand the 
osteoblasts. Hence we are requesting for a total of 60 rats.
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